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The TRIP-Br proteins (TRIP-Br1 and TRIP-Br2) are a novel family of transcriptional 
regulators that have been proposed to function as “integrators” at E2F responsive 
promoters to integrate signals provided by PHD zinc finger- and/or bromodomain-
containing transcription factors.  In order to further elucidate the mechanism(s) 
involved in the regulation of human TRIP-Br1 activity and function, the physiological 
interactions of the TRIP-Br1 protein with several key regulatory factors known to be 
involved in protein-protein interactions with TRIP-Br1 were characterized. Co-
immunoprecipitation assays with exogenously co-overexpressed proteins were used 
to determine in vivo interactions between hTRIP-Br1-HA and DP1, E2F1 and/or p53.  
As previously reported, DP1 interacted strongly with hTRIP-Br1-HA.  Utilization of 
a panel of newly constructed hTRIP-Br1-HA truncation mutants successfully 
identified a putative minimal region for binding to DP1 to residues 40-50 on hTRIP-
Br1.  This region maps to the beginning of the putative heptad repeat as well as the 
SERTA domain, which is conserved in an extended family of structurally similar 
proteins that include TRIP-Br1 and TRIP-Br2.  Similarly, the DCB1 domain on DP1 
was postulated to be the minimal binding region for hTRIP-Br1, as determined by a 
combination of empirical observation and a review of published data.  Notably, p53 
was observed to be a component of the E2F1/DP1/hTRIP-Br1-HA quaternary 
complex and may interact directly with hTRIP-Br1-HA.  TRIP-Br1 interactions with 
its binding partners affected its intracellular protein levels, suggesting the existence of 
a form of post-translational regulation most likely due to enzymatic modifications of 
specific amino acid residues.  It was demonstrated that DP1 interaction protected 
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hTRIP-Br1-HA from rapid degradation, resulting in persistently elevated intracellular 
protein levels.  E2F1, on the other hand, accelerated the turnover of hTRIP-Br1-HA, 
with or without DP1 co-overexpression.  Preliminary data suggested that p53 also 
augments hTRIP-Br1-HA turnover.  It was demonstrated that interaction between 
hTRIP-Br1-HA and DP1 is important for their translocation and co-localization into 
the nucleus.  Introduction of site-directed mutations/deletions within the N-terminal 
end of the SERTA domain resulted in a dramatic increase in hTRIP-Br1-HA 
transcriptional co-activation function in a reconstituted E2F1/DP1 reporter system in 
a manner that was independent of DP1 interaction.   Persistent levels of hTRIP-Br1-
HA ∆12-73 suggested that the increase in activity was a consequence of higher 
protein levels.  In summary, the results support a regulatory model in which hTRIP-
Br1-HA is able to promote DP1 nuclear localization through post-translational 
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1. The TRIP-Br (Transcriptional Regulator Interacting with the PHD-
Bromodomain) family of regulatory proteins 
1.1 Historical Perspective 
The Plant Homeodomain (PHD) zinc finger (Figure 1) [1-3] and the bromodomain 
(Figure 2) [4] are evolutionarily conserved domains found in a host of nuclear factors 
implicated in chromatin remodeling and gene transcriptional regulation in 
mammalian cells.  The murine TRIP-Br1 (mTRIP-Br1) protein was originally 
identified in a yeast 2-hybrid screen as a novel mammalian interactor of the 
composite PHD-bromodomain of the transcriptional co-repressor KRIP-1 (TIF1β)  [5, 
6].  Preliminary analyses of the novel gene showed that it encoded a protein that 
possessed structural and functional features of a transcriptional regulator, this novel 
protein was named as TRIP-Br1 (Transcriptional Regulator Interacting with the PHD-
Bromodomain 1).  A BLAST search identified an orthologous full-length human 
TRIP-Br1 cDNA as well as a highly homologous full-length human cDNA of 
unknown function designated KIAA0127 (Genebank accession number D50917) [6].  
Based on structural and functional homology to hTRIP-Br1, KIAA0127 was 
designated as hTRIP-Br2.  Two additional mammalian members of the TRIP-Br gene 
family and a Drosophila homolog have recently been identified in the aftermath of 
the completion of the Human Genome Project [7, 8] .  The work comprising this 
thesis focuses on the characterization of the TRIP-Br1 and TRIP-Br2 proteins. 
3  
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FIGURE 1 Schematic diagram of the structure of the C4HC3 Plant 













FIGURE 2 Ribbon 3D structure representation of the bromodomain 
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1.2 Structural features of the TRIP-Br proteins 
The human TRIP-Br1 (hTRIP-Br1) gene encodes a protein of 236 amino acids with a 
predicted molecular weight of 25.1 kDa and a pI of ~3.99.  The murine TRIP-Br1 
(mTRIP-Br1) orthologue is 86% identical to hTRIP-Br1 in amino acid sequence.  The 
other TRIP-Br family member, the human TRIP-Br2 (hTRIP-Br2) gene, encodes a 
protein of 314 amino acids with a predicted molecular weight of ~33.9 kDa and a pI 
of ~4.12.  The murine orthologue amino acid sequence is 81% identical to that of 
hTRIP-Br2 demonstrating the high degree of evolutionary conservation and 
underscoring the functional importance of this gene family. 
 
Alignment of TRIP-Br1 and TRIP-Br2 primary amino acid sequence identified three 
regions of significant homology (Figure 3).  These domains are designated as TRIP-
Br Homology Domain (THD) 1, 2 and 3 respectively [6].  THD1 is at the amino-
terminal region of TRIP-Br proteins (residues 1-81 of hTRIP-Br1) with 30% identity 
between hTRIP-Br1 and hTRIP-Br2.  Within THD1 lies a putative nuclear 
localization signal [9] embedded within a putative cyclin A binding motif [10] and a 
hydrophobic heptad repeat (zipper) [11, 12].  The putative heptad repeat domain is 
predicted to adopt an amphipathic α-helical conformation and has been shown to 
mediate homodimeric and heterodimeric interactions between TRIP-Br1 and TRIP-
Br2 by GST pull-down experiments of rabbit reticulocyte lysate in vitro translation 
products [S. I.-H. Hsu, E. O’Leary, J. V. Bonventre; unpublished data]. 
 
 THD2 is 19% identical between hTRIP-Br1 and hTRIP-Br2.  The THD2 
domain is proline, acidic, serine and threonine residue rich, which are hallmarks of 
5  
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the PEST sequence frequently associated with proteins with short half-lives or high 
turn-over rates [13].  Notably, according to the PESTFind online software [14], 
THD2 forms the main portion of a predicted weak PEST sequence (Figure 4). 
 
THD-3, the carboxyl-terminal region (residues 167-220 of hTRIP-Br1) has the 
highest degree of homology between TRIP-Br1 and TRIP-Br2 of 33%.  This domain 
is also significantly conserved with the MDM2 acidic transactivation domain [6].  
MDM2 is a p53-associated oncoprotein that inhibits p53-mediated transactivation 
[15] and that stimulates E2F-1/DP-1-dependent transcriptional activities [16].  From 
deletion analyses, amino acid residues 161-178 at the beginning of THD-3 of TRIP-
Br1 were demonstrated to interact with the composite PHD-bromodomain regions of 
KRIP1, TIF1α and SP140 [6].  The THD-3 region that is predicted to adopt an α-
helical structure and to act as a protein-protein interaction interface with the PHD-
bromodomain motif is also the most highly conserved region among all murine and 
human TRIP-Br homologues and orthologs.  
 
Recently, two additional members of the mammalian TRIP-Br family have been 
identified (RBT1 and Hepp) along with a Drosophila ortholog (Tara) [8, 17, 18].  A 
novel conserved motif designated the SERTA (conserved domain between 
SEI1/TRIP-Br1, RBT1 and TARA) domain was identified as common to all TRIP-Br 
family members and spans residues 38-85 in hTRIP-Br1 (Figure 4) [8, 19].  It is the 
largest conserved domain between the TRIP-Br proteins but the physiologic function 
of this domain has not been elucidated.  Notably, the 48 amino acid residue SERTA 
6  
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domain is also the most highly conserved domain among TRIP-Br family members 
and their orthologs and ortholog subgroups (Figure 5).  
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30% 19% 33% Percentage homology 
1 23 43 81 
SERTA domain (38-85) 
FIGURE 3 Putative domain structure of human TRIPBr1 AND 
TRIP-Br2. 
The extent of homology between the THDs of hTRIP-Br1 and hTRIP-Br2 proteins 
are shown as percentages.  The PHD-Bromodomain interacting region was identified 
at the N-terminal end of THD-3.  Furthermore, a highly conserved SERTA domain 
was recently identified. 
THD: TRIP-Br Homology Domain; SERTA: Conserved domain between SEI1/TRIP-
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FIGURE 4 PEST analysis of human TRIP-Br1 primary sequence. 
[13, 14] 
 
PESTFind analysis software (online) was used to identify potential PEST sequences 
within TRIP-Br1.  Although there were no potential PEST sequences identified, the 
majority of human TRIP-Br1 qualified as poor PEST sequences. 
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FIGURE 5 Sequence alignment of human TRIP-Br1 domains with 
respective domains in other similar proteins using ClustalW 
program.  Adapted from [19] 
 
The sequences were aligned as above using the ClustalW program.  Identical amino 
acids are indicated by ‘*’ while positions at which there is amino acid similarity are 
indicated by ‘.’ below the alignment.  The GenBank or ENSEMBL accession 
numbers are as follows: Human CDCA4 NP_060425, chimpanzee CDCA4 
XP_510205, mouse CDCA4 NP_082229, rat CDCA4 XP_576107, chicken Cdca4 
CAG31546, Xenopus laevis Cdca4 AAH76787, Xenopus tropicalis Cdca4 
NP_001016649, zebrafish Cdca4 NP_001008580, Tetraodon nigroviridis Cdca4 
CAG03781, Takifugu rubripes Cdca4 (NEWSINFRUP00000147300), human TRIP-
Br2 XP_376059, mouse TRIP-Br2 NP_067347, rat TRIP-Br2 
ENSRNOP00000007162, chicken TRIP-Br2 ENSGALP00000014316, zebrafish 
TRIP-Br2 NP_997959, Tetraodon nigroviridis Trip-Br2 CAG00367, Takifugu 
rubripes Trip-Br2 SINFRUP0000016473, human RBT-1 NP_037500, mouse RBT-1 
NP_573473, human TRIP-Br1 NP_037508, mouse TRIP-Br1 NP_061290 and rat 
TRIP-Br1 XP_341881, Drosophila taranis-1α AAN13701, Apis mellifera ‘Similar to 
CG6889-PA’ XP_394534, human SERTAD4 NP_062551, mouse SERTAD4 
NP_937890, rat SERTAD4 XP_341175, Tetraodon nigroviridis ‘Novel SERTA 
domain’ CAF99004, Drosophila ‘Similar to SERTAD4’ CG2865-PA NP_569997.   
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1.3 The functional properties of the TRIP-Br proteins. 
1.3.1 Co-regulation of the E2F-1/DP-1 transcriptional activity 
TRIP-Br1 was demonstrated to physically interact with DP1 in vitro and in vivo [6].  
The TRIP-Br proteins were predicted to function as co-activators of E2F-1/DP-1 
based on the observation that the C-terminal putative transactivation domain shares 
significant homology with the MDM2 transactivation domain that has been 
previously reported to co-activate E2F1/DP1.  It was demonstrated in luciferase 
reporter analyses in SAOS-2 osteosarcoma cells that the TRIP-Br1 and TRIP-Br2 
proteins co-activated E2F-1/DP-1 transcriptional activity on the endogenous B-myb 
and the p107 promoter in a dose-dependent manner [6].  This strongly suggests that 
TRIP-Br recruitment to the E2F1/DP1 through interaction with DP1 is a novel 
mechanism for the regulation of E2F1/DP1 transcriptional activity. 
 
1.3.2 TRIP-Br proteins possess potent acidic transactivation domains 
The mechanism of TRIP-Br co-activation of E2F1/DP1 transactivation activity was 
determined by overexpression of GAL4-TRIP-Br1 and GAL4-TRIP-Br2 fusion 
proteins on a heterologous promoter bearing GAL4 DNA binding sites.  Both TRIP-
Br proteins functioned as potent and dose-dependent transcriptional activators in 293, 
COS7, and LLC-PK1 porcine epithelial cells.  Furthermore, deletion analysis mapped 
the transactivation domain to the carboxyl-terminal acidic region of TRIP-Br1 and 
TRIP-Br2 [6].  Hence, TRIP-Br proteins function as transcriptional activators as 
predicted based on the inherent structural features. 
 
11  
Christopher YANG Maolin Yong Loo Lin School of Medicine, NUS 
Ph.D. Thesis  1999-2007 
 
 
1.3.3 The unique ability to interact with the PHD zinc finger and/or the 
bromodomain and its functional significance 
mTRIP-Br1 was first identified as an interactor with the composite PHD zinc finger- 
bromodomain region of the transcriptional co-repressor KRIP-1 [5] in a yeast two-
hybrid screen.  TRIP-Br1 was subsequently shown to interact with full-length KRIP1, 
TIF1α and SP140, as well as p300 [20] and NF-X1 [21], all of which possess PHD 
zinc fingers and/or bromodomains. Both TRIP-Br1 and TRIP-Br2 interacted with the 
PHD-bromodomain of KRIP-1 as well as full-length KRIP-1 in in vitro pull down 
assays, demonstrating that the interaction between TRIP-Br proteins and KRIP-1 is 
mediated through the PHD-bromodomain of KRIP-1 [6].  These findings identified 
TRIP-Br1 and TRIP-Br2 as a novel family of proteins endowed with the unique 
ability to interact with the PHD zinc finger and/or the bromodomain in structurally 
and functionally related and unrelated transcriptional regulators.  
 
When either GAL4-TRIP-Br1 or GAL4-TRIP-Br2 was co-expressed with a 
heterologous minimal promoter construct in a luciferase reporter assay, KRIP-1 co-
expression further augmented the transcriptional activity of both TRIP-Br proteins.  A 
mutant version of KRIP-1 (KRIP-1 ∆RBCC ∆PHD), in which the RBCC tripartite 
motif and the PHD-bromodomain of KRIP-1 had been deleted, lacked transcriptional 
co-activation function, suggesting that the co-activation function is mediated through 
the deleted RBCC tripartite motif and/or the composite PHD-bromodomain [6]. 
p300/CBP, a PHD zinc finger- and bromodomain-containing co-activator/adaptor, has 
also been reported to possess the ability to co-regulate the transactivation function of 
TRIP-Br1 and TRIP-Br2 [22].  Furthermore, reconstituting the more physiologic 
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context of a E2F1/DP1/TRIP-Br complex on an E2F-responsive promoter, co-
expression of KRIP-1 had the ability to further augment the transcriptional activity of 
E2F1/DP1/TRIP-Br [6].  This suggests that KRIP-1 cooperates with the TRIP-Br 
proteins to co-activate E2F-1/DP-1. 
 
The retinoblastoma protein (RB) had previously been shown to physically interact 
and mask the transactivation domain of the E2F1 transcription factor, suppressing its 
transcriptional functions as a means of gene transcriptional regulation.  As expected, 
the co-expression of RB abolishes baseline E2F1/DP1 transcriptional activity as well 
as TRIP-Br/KRIP-1 co-activation [6].  However, the observed repression is 
completely reversed with expression of the E1A oncoprotein, which has been shown 
to bind strongly to RB, sequestering it from E2F1 [23].  
 
The above results strongly demonstrate that the TRIP-Br proteins regulate the 
E2F1/DP1 transcriptional activity by recruitment of various PHD zinc finger- and/or 
bromodomain-containing proteins to the E2F1/DP1 complex.  The co-activation of 
E2F1/DP1 by the TRIP-Br proteins and KRIP-1 occurs in a manner that is consistent 
with previously reported observations of RB and E1A regulation of the E2F1/DP1 
transcriptional complex.  
 
1.3.4 The TRIP-Br proteins: a novel class of cell cycle regulators 
Independently reported in 1999 as p34(SEI-1) [17] and in 2001 as TRIP-Br1 [6] in 
studies aimed at identifying interactors to p16INK4a and the composite PHD zinc 
finger-bromodomain of KRIP-1, respectively, progress in elucidating the 
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physiological function of the TRIP-Br proteins has advanced gradually but has left 
many questions unanswered [6, 17, 24-28].  Notwithstanding, the emergent findings 
thus far are consistent with a role for the TRIP-Br proteins in E2F-mediated gene 
transcriptional activity and cell cycle regulation.  Evidence from several studies 
corroborates the multiple roles of TRIP-Br proteins as regulators of cell cycle 
progression. 
1. TRIP-Br proteins regulate the transcriptional activities of E2F/DP 
transcription factors [6, 24]; 
2. TRIP-Br proteins interact physically with the cell cycle regulatory 
protein cyclin A [Hsu, S.I., unpublished data[28]]; 
3. The expression of hTRIP-Br1 is regulated by differential expression 
during the cell cycle [6]; 
4. hTRIP-Br1 binds to CDK4 and modulates its kinase activity [17, 26]; 
5. hTRIP-Br1 regulates p53-dependent transcriptional regulation [27]. 
 
1.3.5 Functional relationships between the TRIP-Br proteins and the E2F family of 
transcription factors 
The functions and activities of E2F and DP proteins, represented by E2F1 and DP1 
here, have been extensively reported and reviewed [29-35]. The E2F/DP complexes 
were identified and later defined by the DNA binding properties to a recognition 
sequence present in the adenovirus E2 promoter.  Both TRIP-Br proteins have the 
ability to co-regulate the E2F1/DP1 transcription complex transcriptional activity, 
thereby affecting the co-ordination of the periodicity that is characteristic of the 
activity of the various components of the cell cycle machinery [12]. 
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For E2F proteins to function as transcriptional regulators, heterodimerization with the 
DP partners is a prerequisite [32].  E2F proteins are unable to bind DNA by 
themselves while DP proteins are cytoplasmic and require interaction with E2F 
protein partners for nuclear translocation [36].  This reflects the intimate 
interdependency between the two proteins.  In mammalian cells, there are currently 
seven E2F genes (encoding E2F1, E2F2, E2F3a, E2F3b, E2F4, E2F5, E2F6, E2F7a 
and E2F7b) and two DP genes (encoding DP1 and DP2) [37-39].  E2F and DP 
proteins, generally, possess highly conserved DNA-binding domains and dimerization 
domains (Figure 6) [37, 40].  The E2Fs can be classified into subgroups based on 
their structure, affinity for members of the pRB family, expression pattern and 
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FIGURE 6 Domain organization of members of the E2F family. [38] 
The identified domains within E2F family members are shown in the schematic 
above, namely, cA, Cyclin A binding site; DB, DNA binding domain; DIM, 
dimerization domain; TA, transactivation domain; PB, pocket protein (pRB family) 
binding domain.  Number of amino acids is indicated on the right. Shaded boxes 
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TABLE 1 E2F family members classified according to functional 
and physical characteristics. 




• Associate exclusively with pRB at 
physiological levels 
• Ectopic expression is sufficient to induce S-
phase in serum-starved tissue culture 
• Mainly involved in the regulation of cell 
proliferation and apoptosis 
2 E2F4 & E2F5 
• Associate with all three pRB family members 
• Expression is not cell cycle regulated 
• Unable to induce S-phase in quiescence cells 
• Mainly involved in the regulation of 
differentiation and development 
3 E2F6 • Lacks the domains involved in transactivation and binding to the pRB family 
• Physiological function(s) remains unclear 
4 E2F7 
• Lacks the domains involved in dimerization, 
transactivation and binding to the pRB family 
• Physiological function(s) appear to be a 
suppressor of a subset of E2F responsive gene 
promoters. 
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The classification in Table 1 divides the E2F family into activators and repressors 
since E2F, although traditionally described as a transcriptional activator, can also act 
as a repressor depending on the context [i.e. E2F family member involved with the 
consequent pocket protein regulators (pRB, p107 and p130)] [42, 43].  Pocket 
protein-bound E2Fs are rendered transcriptionally inactive due to direct binding to 
and steric masking of the transcriptional domains on E2Fs, resulting in transcriptional 
repression of E2F-responsive genes.  Furthermore, pocket proteins recruit Histone 
Deacetylases (HDACs) and the chromatin-remodelling factors of the SWI/SNF 
family.  HDACs are enzymes that deacetylate histone octamer tails and thereby 
induce nucleosomal condensation, while SWI/SNF complexes utilize ATP to 
assemble nucleosomes, essentially inhibiting transcription factor access to the 
promoter. 
 
The pocket protein (E2F-inhibition) activity is regulated by its phosphorylation status 
as determined by the cell cycle activities of cyclin-dependent kinases (CDK).  When 
hypophosphorylated, pocket proteins bind to E2Fs and render the DNA-bound 
E2F/DP complex transcriptionally inactive.  Hyperphosphorylation of pocket proteins 
by the appropriate cyclin/CDK complexes results in a conformational change and 
subsequent release from E2Fs.  In the quiescent state (G0 phase), the E2F 
transcription factors are associated with members of the pocket protein family, 
namely pRB, p107 and/or p130.  When bound, the E2F/DP transcription complex is 
kept in an inactive state.  When cells are stimulated to enter the cell cycle and 
undergo DNA replication and mitosis, the E2F-bound pocket proteins are 
hyperphosphorylated by the CyclinD-CDK4 and CyclinE-CDK2 complexes, leading 
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to their dissociation from E2Fs.  The release of E2F/DP complexes from RB-
mediated transcriptional inhibition gives rise to expression of the relevant E2F-
responsive genes.   
 
Although E2F proteins have been distinctively characterized, the discrete roles for DP 
(also known as DTRF) proteins have not been well-defined.  Emerging data indicates 
that DP proteins may play significant roles in cell cycle regulation, rather than acting 
as silent partners to E2Fs as previously thought.  Recent data have found DP 
interacting proteins which include the oncoprotein p53, the adenovirus E4 protein, 
and the BTB/POZ-containing DIP (DP1 Interacting Protein) [44-46].  Furthermore, 
DP proteins are not directly bound by or regulated by pocket proteins.  The 
expression and protein regulation profile of DP1 is distinctly different from its E2F 
counterpart, as it is constitutively expressed and mainly cytoplasmic [36, 47].  Its 
activity is dependent on nuclear localization via heterodimerization with the 
appropriate E2Fs, usually taken as E2F1 [36, 40].  Notably, DP1 was recently found 
to have an isoform that did not translocate into the nucleus and appeared to negatively 
regulate cell cycle progression [40].  The emerging data, including TRIP-Br 
interaction and physiological functions with DP1, clearly suggests an alternative and 
complementary cell cycle regulatory mechanism mediated by DP1. 
 
As one of the key effectors of the G1-S transition, the E2F/DP complex controls 
progression of the cell cycle.  TRIP-Br protein interaction with the DP1 component of 
the E2F/DP complex places TRIP-Br proteins in a position to influence cell cycle 
progression.  Together with the PHD-bromodomain binding property of TRIP-Br 
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proteins, TRIP-Br proteins may function to “fine tune” the regulation of the 
transcriptional readout of E2F-responsive genes by “integrating”  both positive and 
negative signals conferred by PHD zinc finger- and/or bromodomain-containing 
transcription factors, many of which have been implicated in chromatin-remodelling.  
 
1.3.6 Cell cycle regulated expression of human TRIP-Br1 
Besides its interaction with DP proteins and PHD-bromodomain containing proteins, 
the endogenous expression of TRIP-Br1 was discovered to be differentially regulated 
throughout the cell cycle, with increasing levels throughout G1 and peaking during S 
phases [6].  The observed regulation of TRIP-Br1 circadian expression profile 
suggests that it is involved in S phase traversal, likely through co-regulation with the 
E2F/DP complex. 
  
1.3.7 Human TRIP-Br1, a CDK4-interacting regulatory protein 
In an independent study, p34SEI1 (TRIP-Br1) expression was demonstrated to be 
rapidly induced in quiescent fibroblasts upon serum addition.  Furthermore, under 
low serum conditions, overexpression of TRIP-Br1 enabled fibroblast proliferation, 
thereby supporting a proposal that TRIP-Br1 may act as a growth factor sensor [17].  
TRIP-Br1 was also found to activate the CyclinD/CDK4/p16 complex through a 
direct interaction with CDK4 and activation of its kinase activity despite the 
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The model of TRIP-Br protein function in cell cycle regulation 
Hsu et al (2000) [6], proposed a model based on the previously mentioned 
observations and findings.  In this model, a dual role for hTRIP-Br1 in the regulation 
of mammalian cell cycle progression was postulated (Figure 7).  CDK4 is inactivated 
by its binding with the CDK inhibitor (CKI), p16INK4a [48-50]. When stimulated by 
mitogenic signals, TRIP-Br1 binds to the complex through a direct interaction with 
CDK4, which allows Cyclin D binding to CDK4 simultaneously with p16INK4a to 
form a functionally active quaternary complex [17].  This complex 
hypophosphorylates pRB in late G1 as well as activates the Cyclin E-CDK2 kinase 
complex, which consequently also contributes to pRB hyperphosphorylation and 
dissociation of pRB from E2F1.  Following pRB dissociation, TRIP-Br1 then binds to 
DP1 and results in the assembly of E2F1/DP1/TRIP-Br ternary complexes [6].  The 
TRIP-Br proteins serve as “integrators” to recruit PHD zinc finger- and/or 
bromodomain-containing transcription regulators through their unique PHD-
bromodomain-interacting properties.   
 
Furthermore, it was recently demonstrated that TRIP-Br proteins were essentially 
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FIGURE 7  The model of the TRIP-Br Protein Functions. 
In response to mitogenic stimulation and in the presence of TRIP-Br1 (step 1), cyclin 
D associates with CDK4 simultaneously with p16INK4a (step 2) to form a functionally 
active quaternary complex [17].  This complex contributes both to cyclin E-CDK2 
activation and hypo-phosphorylation of RB (step 3).  The hypo-phosphorylated RB 
bound to transcriptionally inactive E2F-1/DP-1 complexes serves as a hyper-
phosphorylation target of cyclin E-CDK2 (step 4), resulting in the dissociation of RB 
and release of cells from the late G1 checkpoint.  Upon RB dissociation, TRIP-Br1 is 
recruited to the E2F-1/DP-1 complexes on E2F-responsive promoters through 
physical association with DP-1 (step 5), resulting in the assembly of an E2F-1/DP-
1/TRIP-Br1 ternary complex.  PHD zinc finger- and/or bromodomain-containing 
proteins such as p300/CBP and KRIP1 compete for binding to TRIP-Br proteins and 
confer positive (+) or negative (-) regulatory signals to E2F-1/DP-1 transcription 
complexes assembled on E2F-responsive promoters (step 6).  An “integrated” 
transcriptional read-out is achieved by effects on the basal transcriptional machinery.  
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2. Protein post-translational regulation and modification 
2.1 Common regulatory mechanisms of protein activity 
The regulation of protein functional activity plays a critical role in the cell.  The 
timing and co-ordination of protein activities need to be tightly regulated so that 
cellular events can proceed appropriately.  The regulation of protein activity can 
occur through any of a number of mechanisms (often involving multiple pathways 
and complex feedback loops): 1) gene expression (transcriptional regulation); 2) 
maturation and translation of the mRNA (translational regulation); and 2) regulation 
at the protein level (post-translational regulation). 
 
Post-translational regulation of proteins can be envisaged to include three main 
aspects: 1) alterations in sub-cellular localization; 2) post-translational modification; 
and 2) alterations in intracellular protein levels involving protein 
stabilization/degradation.  These categories, though discussed separately, are 
contextually inter-dependent mechanisms.  The following introduction uses examples 
of cell cycle proteins that have recently been relatively well-characterized in terms of 
post-translational regulation, such as ARF1, E2F1, DP1, p53 and MDM2. 
 
                                                 
1 ARF: alternate reading frame protein, also known as p14ARF
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2.2 Protein sub-cellular localization 
2.2.1 Nuclear import and export 
The eukaryotic cell is primarily compartmentalized into the nucleus and the 
cytoplasm by an intracellular membrane, the nuclear membrane, which has selectivity 
in the import and export of proteins.  There are nuclear import and export signals 
(NLS/NES) ‘encrypted’ into the protein primary sequence that upon recognition 
allow the import or export of proteins into/from the nucleus.  Such barriers play a role 
in the regulation of a protein’s activity simply by affecting the co-localization of 
interacting proteins.  DP1 is a constitutively expressed DNA-binding transcriptional 
regulator which lacks a nuclear localization signal (NLS) and is present primarily in 
the cytoplasm [34, 36].  DP1 was found to translocate into the nucleus upon 
heterodimerization with E2F proteins (and more recently with ARF).  It is these DP1 




The sub-cellular localization of DP1 proteins, and thus its activity, is also affected by 
the absolute concentration of DP1 in the appropriate location.  Constitutively 
expressed and lacking a NLS, DP1 is abundant in the cytoplasm where it possesses no 
relevant physiological activity [36].  When co-translocated with an NLS-containing 
binding partner into the nucleus, DP1 appears to have two fates: either to function as 
a transcriptional regulator or to be degraded.  The fate of DP1 appears to depend on 
the binding partner with which it co-translocates into the nucleus.  When DP1 is 
translocated into the nucleus by interaction with E2F1, DP1 primarily functions as 
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part of the E2F/DP heterodimeric transcriptional regulator within the nucleus [47].  
However, ARF is also able to bind to and translocate DP1 into the nucleus [36].  In 
the absence of E2F12, ARF localizes DP1 in the nucleoli and DP1 is rapidly 
degraded.  Thus, available DP1 protein levels are reduced within the nucleus due to 
accelerated proteolysis of DP1 induced by ARF interaction (in the absence of E2F) 
[36]. 
 
2.3 Post-translational modifications (PTM) 
2.3.1 Phosphorylation 
Phosphorylation of proteins is the most extensively characterized form of post-
translational modification of proteins described in the literature.  Protein 
phosphorylation entails the enzymatic addition of phosphate groups onto serine, 
threonine or tyrosine side group chains.  Phosphorylation is widely used in eukaryotic 
cells for the reversible regulation of protein activity through mechanisms such as 
activation/inactivation of protein, sub-cellular localization and interaction between 
protein binding partners. 
 
For example, the intricate relationship between p53 and MDM2 hinges on the 
phosphorylation status of specific residues in each protein [51-57].  Stress signal 
cascades converge upon p53 through phosphorylation of serine and threonine residues 
by kinases (which are themselves also activated by phosphorylation).  There are 17 
phosphorylation (and dephosphorylation) sites on p53, namely serines (Ser) 6, 9, 15, 
20, 33, 37, 46, 149, 315, 376, 378 and 392, and threonines (Thr) 18, 55, 81, 150, 155 
                                                 
2 In the presence of both E2F1 and ARF, E2F1 preferentially binds with DP1 and ARF is excluded. 
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[58] (See Figure 8).  The phosphorylation of p533 consequently results in stabilization 
and activation of p53 protein within the nucleus [51].  
 
The MDM2 protein is comprised of  nearly 20% serine or threonine amino acid 
residues; the protein is phosphorylated at multiple sites within two clusters [59] 
(Figure 9).  Recently, Ser17 phosphorylation was identified to be critical for the 
binding and regulation of p53 by MDM2.  Mutational analysis showed that the ability 
of the S17A mutant to bind to p53 is unaltered after DNA-PK phosphorylation, 
whereas wild-type MDM2 exhibited a significant loss in its ability to bind to p53 
[55].  A NMR analysis of the N-terminal structure of MDM2 indicated that amino 
acid residues 16-24 of MDM2 could form a flexible arm that folds back to stabilize 
the MDM2 structure and may be able to compete with p53 for binding to the cleft 
formed by residues 25-109 [55].  Recent studies have also provided supporting 
evidence for a model in which MDM2 regulation of p53 is inhibited by direct 
phosphorylation of MDM2 by the ataxia telangiectasia mutated (ATM) protein 
kinase.  Phosphorylation by ATM is proposed to enhance the nuclear export of 
MDM2 [60].  Furthermore, c-Abl has been shown to directly interact with and 
phosphorylate MDM2 on Tyr394 [56].  Failure of phosphorylation at this site 
increases MDM2-mediated p53 degradation, and consequently down-regulates p53-
dependent transactivation.  Notably, c-Abl is also regulated through post-translational 
phosphorylation by ATM [60]. 
 
                                                 
3The overall phosphorylation status rather than independent phosphorylation events are important for 
the co-ordination of p53 activity. 
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Another pathway of phosphorylation-mediated MDM2 regulation of p53 comes from 
a recently proposed model whereby Akt kinase activation results in MDM2 Ser166 
and Ser 186 phosphorylation [54, 56, 57, 61, 62].  These two residues are located 
close to the NLS and NES4 of MDM2 such that phosphorylation at these sites 
promotes nuclear import.  MDM2 mutants that had Asp166 and Asp186 substitutions 
(mimicking constitutive phosphorylation) were observed to have nuclear localization, 
independent of Akt phosphorylation [61].  The consequence of phosphorylation of 
MDM2 at Ser166 and Ser186 is stimulation of p53 degradation.  The same 
phosphorylation status also inhibits MDM2 interaction with its negative regulator, 
ARF [63]. 
 
Therefore, it has been well demonstrated that post-translational protein 
phosphorylation not only acts as a molecular switch to activate/inactivate the activity 
of a protein, but also serves to regulate protein activities through inter-dependent 
mechanisms such as sub-cellular localization and protein-protein interactions. 
                                                 
4 Nuclear Localization Signal (NLS); Nuclear Export Signal (NES) 
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FIGURE 8  Phosphorylation sites of human p53.  [58, 64] 
The most common post-translational modification of p53 is phosphorylation.  At this 
time, 17 serine and threonine sites have been reported to be phosphorylated on p53. 
Most of the sites are located in the amino terminal region.  Some protein kinases 
phosphorylate numerous sites; several sites are phosphorylated by more than one 
protein kinase. Each site and the kinase(s) responsible for the phosphorylation are 
indicated.  
ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3 related 
protein; AURKA, aurora kinase A; CDK, cyclin-dependent kinase; CHK, checkpoint 
kinase; CK,casein kinase; CSN-K, COP9 signalosome associated kinase complex; 
DNA-PK, DNA-dependent protein kinase; ERK, extracellular signal-regulated 
kinase; GSK3β, glycogen synthase kinase-3β; HIPK2, homeodomain-interacting 
protein kinase 2; JNK, c-JUN NH2-terminal kinase; MAPKAPK2, mitogen-activated 
protein kinase-activated protein kinase 2; NES, nuclear export signal; NLS, nuclear 
localization signal; p38, p38 kinase; PKC, protein kinase C; REG, carboxy-terminal 
regulatory domain; SH3, Src homology 3-like domain; TAD, transactivation domain; 
TET, tetramerization domain. 
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FIGURE 9 Schematic diagram showing the functional domains and 
phosphorylation events impinging on MDM2. [60] 
The amino acid residues are numbered. Functional domains of the MDM2 protein 
including the p53 binding domain, nuclear localization sequence (NLS), nuclear 
export sequence (NES), acidic domain, zinc finger, RING finger, and nucleolar 
localization sequence (NoLS) are indicated. The positions of the phosphorylation-
sensitive epitopes for monoclonal antibodies SMP14 and 2A10 are also given. 
Phosphorylation sites are indicated by the letter P within an ellipse. Their locations 
relative to the functional domains of MDM2 are shown. Protein kinases, where 
known, are indicated in boxes with the target residue(s) shown above. The effects of 
individual phosphorylation events are indicated: a vertical arrow signifies stimulation, 
whereas an inverted ‘‘T’’ indicates inhibition. 
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Another important PTM is acetylation.  Acetylation is the addition of acetyl groups 
onto the έ-amino group of lysine residues (Figure 10).  In recent years, the 
significance of acetylation as a mechanism for the regulation of protein functional 
activity has become firmly established.  Many proteins have been found to be 
acetylated and its protein activity regulated through acetylation status, similar to the 
paradigm of phosphorylation.  Perhaps the best known classical example of 
acetylation-mediated regulation of protein activity is that of eukaryotic histone 
acetylation/deacetylation.  Chromosomal compaction depends on the acetylation 
status of histone tails.  When histone tails are acetylated, chromosomal DNA is not 
tightly bound by histone proteins [65].  Histone deacetylases (HDACs) remove acetyl 
groups from histones resulting in tight binding of deacetylated histones to chromatin.  
Transcriptional silencing is achieved by hindering access of DNA-binding regulatory 
proteins to histone-bound chromatin [66-68]. 
 
Recently, other non-histone proteins, especially transcriptional regulators, have been 
found to be acetylated in a manner that modulates protein activity.  For example, in 
addition to being regulated by phosphorylation, p53 is also regulated by acetylation.  
The p53 oncoprotein is acetylated by CBP/p300 and PCAF acetyltranferases at 
Lys373/Lys382 and Lys320, respectively [69-72].  p300 also uniquely acetylates 
Lys305 of p53 [73].  Acetylation of these lysine residues has been shown to be 
important for the regulation of transcriptional activity and stabilization of p53.  The 
significance of this regulatory mechanism is confirmed by the finding that oncogenic 
mutant p53 is found to be hyperacetylated at Lys320, Lys373 and Lys382, while 
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wild-type p53 is only weakly acetylated at these residues [74].  The Hepatitis C Virus 
(HCV) core protein induces hyper-acetylation of Lys373 and Lys382 residues and is 
predicted to affect the stability of p53 [75].  RAS-induced overexpression of the 
Promyelocytic Leukemia (PML) protein also results in acetylation of the Lys382 
residue of p53 [76].  
 
Conversely, it has been demonstrated that deacetylation of p53 results in an increase 
in p53 degradation by MDM2.  The SIRT1 protein was identified as the deacetylase 
responsible for deacetylating p53 at Lys382, resulting in a concomitant decrease in 
p53-mediated transcriptional activity [77].  Inhibition of the SIRT1 deacetylase 
resulted in p53 stabilization. 
 
Notably, CBP/p300 also inactivates MDM2 by acetylation.  The regulatory network 
to which MDM2 belongs has been shown to be quite intricate, as MDM2 also 
regulates PCAF by ubiquitination through its E3 ubiquitin ligase activity [78, 79].  
Furthermore, MDM2 inhibits p53 acetylation through its interactions with CBP/p300 
[80]. 
 
The regulation of p53-mediated transcriptional activity by acetylation is likely the 
consequence of protein stabilization.  This stabilization is thought to be achieved 
through the inhibition of ubiquitination, as the majority of the acetylation sites 
coincide with the residues where ubiquitin is added.  Acetylation may facilitate 
stabilization and accumulation of p53 through the inhibition of ubiquitination.  This 
regulatory mechanism is coordinated with the phosphorylation status of p53 as well 
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as its intracellular localization discussed earlier in order to bring about the 
stabilization of p53 through post-translational modifications and associated regulatory 
mechanisms. 
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FIGURE 10 Acetylated Lysine.   
Attachment of the acetyl group is on the epsilon amino group of the lysine residues.  
Similarly, attachment of other post-translational modification side groups are also on 
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2.3.3 Ubiquitination  and Sumoylation 
Ubiquitin is a small protein of ~75 amino acid residues with a molecular weight of 
8.4 kDa.  Ubiquitin is added onto proteins on the ε-amino group of lysine residues 
through a series of enzymatic reactions mediated by the E1, E2 and E3 enzymes5.  
The ubiquitin modification targets the protein for degradation by the 26S proteosomal 
pathway.   
 
MDM2 is an E3-ubiquitin ligase and catalyses the mono-ubiquitination of p536.  
MDM2 is also capable of auto-ubiquitination.  The choice between targeting p53 or 
itself for ubiquitination appears to be determined by the sumoylation status of MDM2 
[60].  MDM2-mediated ubiquitination of p53 results directly in the destabilization 
and degradation of p53 and is the primary mechanism for the regulation of p53 
activity.  The significance of p53 ubiquitination is based on a proposal that p53 
mono-ubiquitination facilitates nuclear export while poly-ubiquitination (contributed 
by the additional activity of p300) results in p53 degradation [64].  Clearly, 
ubiquitination of proteins, particularly p53, is a mechanism for controlling protein 
activity through regulation of intracellular protein expression levels, which is in part 
influenced by its intracellular localization. 
 
SUMO (small ubiquitin-like modifier) is a recently discovered 97 amino acid residue 
protein that is used as a post-translational modification by its addition to proteins on 
the same site as ubiquitin and acetyl groups (i.e. lysine residues) (Figure 11).  This 
reversible PTM has in recent years been shown to have profound effects in regulating 
                                                 
5 E1 – Ubiquitin activating enzyme; E2 – Ubiquitin conjugating enzyme; and E3 – ubiquitin protein 
ligase 
6 Polyubiquitination of p53 is carried out by p300. 
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protein activity, localization, stability, protein-protein interactions and, in some 
instances, DNA binding (Figure 12).  Mammalian cells have 3 types of SUMO 
modifications, designated SUMO-1, SUMO-2 and SUMO-3.  The sumolyation 
pathway appears to be very similar to that of the ubiquitination pathway (Figure 13) 
[81-83]. 
 
MDM2 is one such protein that is regulated by sumoylation.  It is sumoylated around 
residues 134-212, a region containing Lys136, Lys146, and Lys 185 [60].  SUMO 
modification modulates the MDM2 ubiquitin ligase activity.  With expression of 
mutant Ubc9, which is the enzyme that adds SUMO onto MDM2, a concomitant 
decrease in sumoylated MDM2 was observed [84].  There was a corresponding 
increase in MDM2 ubiquitination and a consequent decrease of p53 ubiquitination.  
Conversely, ARF expression have been found to augment the sumolyation of MDM2, 
thereby providing a mechanism through which ARF blocks the ubiquitination of p53 
[85].  In the case of MDM2, experimental findings demonstrate the significance of 
the regulatory role of SUMO-1 addition on MDM2 protein activities.  Sumolyation 
modulates the MDM2 E3 ligase activity and leads to the stabilization of p53. 
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FIGURE 11 Structure comparison of Ubiquitin and human 
SUMO-1. [82] 
Both proteins share a characteristic tightly packed ββαββαβ fold, and a C-terminal 
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FIGURE 13 The SUMO conjugation pathway. [81] 
SUMO is synthesized as a precursor and processed by hydrolases to make available 
the double glycine.  It is then conjugated to proteins via an E1 activating, E2 
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MATERIALS AND METHODS 
 
3. Materials 
3.1 Cell lines: 
U2OS human osteosarcoma (ATCC No. HTB-96) and Green African monkey COS-7 
(ATCC No. CRL-1651) cell lines were used in the experiments accordingly as stated.  
Both cell lines were cultured in Dubelco’s Modified Eagle’s Medium (DMEM) 
(Sigma product no. D5671), supplemented with 10% fetal bovine serum (FBS) from 
Hyclone (Product no. SH30071.03HI), and incubated in a close vented incubator at 
37oC with 5% carbon dioxide. 
 
3.2 Plasmid DNA and cDNA clones: 
The pCMV/E2F1 was a kind gift from Dr. Tony Kouzarides (Wellcome/CRC 
Institute and Department of Pathology, University of Cambridge).  The pCMV/DP1 
vector construct and the pGL3-6×E2F-TATA/Luciferase reporter plasmid were kind 
gifts from Dr. Kristian Helin (European Institute of Oncology).  The plasmid DNA 
and cDNA clones for in vitro translation (IVT) and transfection experiments have 
been previously described [6].  
 
pcDNA3/hTRIP-Br1-HA was constructed by PCR using the forward primer and 
reverse primer with HA tag encoded (5’-GCAAGATGCTGAGCAAGGGTC-3’ and 
5’-
TCAAGCGTAATCTGGAACATCGTATGGGTAGCCGCGCCCTGGCCCCGGCG
GTC-3’, respectively).  TOPO TA Cloning® (K4500-01) was used to generate EcoRI 
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fragments for ligation into pCDNA3 and PCR conditions were according to 
manufacturer’s instructions.  Mutants were generated in a similar fashion, using the 
wildtype construct as template.  Site-directed mutagenesis was done using the 
Stratagene QuikChange® Site-Directed Mutagenesis Kit (catalog #200518) with the 
relevant primers designed according to manufacturer’s instructions. 
 
3.3 Biochemical reagents: 
Cycloheximide (C 7698) was purchased from Sigma.  MG132 (Calbiochem Cat. No. 
474790) and lactacystin (Santa Cruz Cat. No. SC-3575) were purchased from 
CalBiochem and Santa Cruz, respectively. 
 
All antibodies used were from Santa Cruz Biotechnology, with the exception of 
mouse monoclonal anti-DP1 (Powerclone #05-381) from Upstate Biotechnology. 
Rabbit polyclonal antibodies for cyclin D1 (sc-718), Cdk2 (sc-163), E2F1 (sc-193), 
HA-probe (sc-805) and Geminin (sc-13015), as well as HRP-conjugated anti-rabbit 
(sc-2004) and anti-mouse (sc-2005) secondary antibodies were purchased from Santa 
Cruz Biotechnology. The Protein A conjugated agarose used for immunoprecipitation 
was from Invitrogen (Cat. No. 15918-014). 
 
4. Methods 
4.1 Transformation and maintenance of plasmid DNA clones 
Plasmid DNA samples were introduced into competent DH5α® E. coli cells by 
standard transformation protocols. Briefly, for each transformation, 50 µl of 
competent cells were pre-incubated with 0.85 µl β-mercaptoethanol on ice prior to the 
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addition of plasmid DNA.  After 30 minutes of incubation on ice, the cell-DNA 
mixture was subjected to brief heat-shock at 42oC for 45 seconds and then rapidly 
cooled on ice for 2 minutes. Following the addition of 250 ml SOC media, the cells 
were grown at 37oC for 1 hour under constant agitation (200 revolutions per minute). 
100 µl of the culture was plated on LB agar plates supplemented with ampicillin (100 
µg/ml) and grown overnight at 37oC. Single colonies were picked for screening and 
positive transformants were maintained as glycerol stocks at –70oC for long-term 
storage. 
 
4.2 Mini- and maxi-scale preparation of plasmid DNA from bacteria 
Mini-scale preparation (mini-prep) and maxi-scale preparation (maxi-prep) of 
plasmid DNA from bacteria were performed using the mini-prep and the maxi-prep 
kits (Qiagen Cat. No. 27106 and 16223, respectively) according to the manufacturer’s 
instructions. For mini-preps, plasmid-bearing bacterial cells were inoculated into 5 ml 
of LB media supplemented with the appropriate antibiotics for selection and grown 
overnight in a shaking culture at 37oC. For maxi-preps, a 5 ml starter culture was 
grown for 6-8 hours and then scaled up to 300 ml for overnight culture for 
approximately 16 to 20 hours. 
 
4.3 Quantitation and purity assessment of DNA or RNA 
The concentrations of DNA or RNA preparations were measured by means of 
spectrophotometry (BIO-RAD SmartSpecTM 3000). DNA or RNA purity was 
determined from the A260/A280 absorbance ratio. 
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4.4 Screening of transformants for positive clones 
Restriction enzyme (RE) digest analysis was employed as the basic method to screen 
for desired clones. RE digest analyses were performed on 200 ng of mini-prep 
plasmid DNA using the appropriate restriction endonucleases (New England Biolabs) 
under conditions specified by the manufacturer. Restriction fragments were analyzed 
by agarose gel electrophoresis. 
 
4.5 Agarose gel electrophoresis of DNA products 
DNA products were analyzed by agarose gel electrophoresis in a Hoefer® mini-gel 
horizontal submarine electrophoresis unit (Pharmacia Biotech). Agarose gels (0.7%- 
1.5%) were prepared from Seakem® LE agarose (FMC Bioproducts) with 1X TAE 
(give formula) buffer base. Following electrophoresis, ethidium bromide-stained 
DNA products were visualized using a ultra-violet (UV) trans-illuminator. 
 
4.6 Synthesis of proteins by in vitro translation 
In vitro translation (IVT) products were synthesized from plasmid preparations using 
the TNT T7 coupled reticulocyte lysate system (Promega cat. no. L1170). The in vitro 
translation reactions were carried out, as per manufacturer’s instructions, in a total 
reaction volume of 50 ml by incubating 1.0 µg of the indicated DNA template in 
nuclease-free water with 30 ml of TNT Quick master mix in the presence of 
methionine (Met) at 30oC for 90 minutes. 
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4.7 Preparation of proteins from tissue culture 
Cells grown in tissue culture were washed in cold PBS and lysed in situ in sample 
buffer (50 mM Tris-Cl, pH 6.8, 2% SDS, 10% glycerol, 0.1% bromophenol blue and 
100 mM DTT). Whole cell lysates were heated at 100oC for 10 minutes prior to 
electrophoresis. 
 
4.8 Analysis of proteins by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Proteins were analyzed by Sodium Dodecyl Sulphate (SDS)-PAGE performed with 
1X running buffer (25 mM Tris pH 8.6, 0.19 M glycine, 0.1% SDS) in a mini vertical 
electrophoresis apparatus (BIO-RAD) at constant voltage (90 V). Separation of 
complex protein mixtures was achieved using a discontinuous polyacrylamide gel 
system consisting of a stacking gel and a separating gel. Both the stacking and the 
separating gel were prepared from 30% w/v acrylamide/bis solution [29:1; 3.3% 
cross-linking ratio (BIO-RAD)]. Stacking gel was prepared in upper Tris buffer 
(0.125 M Tris pH 6.8, 0.1% SDS) while separating gel was prepared in lower Tris 
buffer (0.4 M pH 8.6, 0.1% SDS). 
 
4.9 Western blot for protein detection 
Following electrophoresis, proteins were transferred from the gels to nitrocellulose 
membranes (ImmobilonTM-P, Millipore) by electro-blotting (30V overnight at 4oC) 
in transfer buffer (25 mM Tris, 384 mM glycine, 20% methanol, 0.01% SDS). 
Following blocking (1×PBS, 0.5% Tween-20, 4% w/v non-fat milk), target proteins 
were detected using a 1:1,000 dilution of specific primary antibodies. Anti-mouse or 
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anti-rabbit IgG antibodies conjugated with horseradish peroxidase (HRP) (Santa 
Cruz) were used to visualize immunoreactive proteins at 1:2,000 dilutions using 
enhanced chemiluminescence (Pierce). 
 
4.10 Confocal microscopy 
For confocal microscopy, sub-confluent U2OS cells were cultured in 8-well chambers 
mounted on #1.0 German borosilicate glass coverslips (Lab-Tek®) and transfected 
accordingly. 24 hours after transfection, the coverslips (with attached cells) were 
washed with 1X PBS and fixed for 20 minutes at room temperature with in freshly 
made 4% paraformaldehyde/PBS solution (pH 7.4).  The cells were then 
permeabilized with 0.2% Triton-X 100 for 10 minutes at  room temperature and 
rinsed thrice with 1X PBS.  Blocking was done with 200µl of 10% FBS in 1X PBS at 
room temperature for at least 2 hours or at 4oC overnight.  20µl of primary antibodies 
diluted (1:100-1:200) in blocking solution was added onto the coverslips and 
incubated for 2 hours at room temperature.  The coverslips were washed thrice with 
blocking solution at room temperature for 5 minutes each time.  20µl of each 
secondary antibody was added and incubated for 2 hours in the dark at room 
temperature.  Anti-rabbit FITC-labeled and/or anti-mouse TRITC-labeled antibodies 
were used at 1:40 and 1:64 dilution, respectively.  The coverslips were then washed 
thrice, and mounted onto glass slides with about 20µl of Fluorsave.  Cells were then   
imaged with a Carl Zeiss 510 laser-scanning microscope using the plan-neafluar 
40X/0.75 Ph2 objectives (laser excitation wavelength of 488 nm; emission 
wavelength of 500-550 nm).  
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4.11 DNA Transfection and Sequential Dual Luciferase Assay 
Plasmid DNA preparations for transfection were prepared by maxi-prep. Following 
quantitation, plasmid preparations were diluted to 200 ng/µl with sterile double 
deionized water and filter-sterilized (0.2 µm, Minisart®, Sartorius). U2OS cells were 
sub-cultured in 24-well plates, transfected with the indicated plasmids using PolyFect 
(Qiagen Cat. No. 301107). 
 
Cells were passively lysed in 100 µl of passive lysis buffer. A single 20 µl aliquot of 
lysate was immediately used for sequential measurement of luciferase activity using 
the Dual Light System (Tropix). For the various protein overexpression studies, 
U2OS cells in between passages 3 and 10 were sub-cultured at 1×105 cells/10 cm2 for 
24 hours before being transfected with plasmid DNA using PolyFect® in accordance 
with manufacturer’s recommendations (Qiagen Cat. No. 301107). 
 
For immunoprecipitation experiments, U2OS cells were subconfluently plated in 
10cm plates and 24 hours later transfected with a total of 4 µg of plasmid DNA 
(typically 0.5µg of pCMV/E2F1, 1µg of pCMV/DP1 and 2.5µg of pcDNA3/hTRIP-
Br1-HA) with PolyFect (Qiagen Cat. No. 301107), as per manufacturer’s instructions.  
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4.12 Semi-quantitative RT-PCR 
Total RNA extraction was effected using the TRIZOL® Reagent (Life Technologies). 
Four µg of RNA was reverse-transcribed using oligo-dT primers and M-MLV reverse 
transcriptase (Promega) in a total reaction volume of 20 µl. Polymerase Chain 
Reactions (PCR) were carried out on 1 µl cDNA sample in the presence of 25 µM 
deoxyribonucleotide triphosphates (dNTPs) and 40 µM of specific primer pairs in a 
total reaction volume of 25 µl (Table 2). The cycling profile for the 30-cycle PCR 
was as follows: 95oC for 2 minutes, 30 cycles of amplification (95oC for 30 seconds, 
55oC for 30 seconds, 72oC for 30-60 seconds), and 72oC for 10 minutes followed by 
4oC storage. 
 
Sequences of gene-specific primers are listed in Table 2. 
 
Post-PCR samples were analyzed by electrophoresis on 2% agarose gel pre-stained 
with ethidium bromide (EtBr) and intensity of DNA bands was quantified through 
densitometric analysis. 
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TABLE 2 Primer sequences used for RT-PCR and cloning. 
TARGET GENE FORWARD PRIMER (5’Æ3’) REVERSE PRIMER (5’Æ3’) 
β-Actin GTGGGGCGCCCCAGGCACCA CTCCTTAATGTCACGCACGATTC 
CCNA2 (Cyclin A2) ACAGCCTGCGTTCACCATTC CATGCTGTGGTGCTTTGAGGTAG 
Human TRIP-Br1 
Kozack hTRIP-Br1 

















































Legend: hTB1 — human TRIP-Br1; ∆ — denotes the deleted amino acid residues. 
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4.13 Protein degradation analysis 
Transfected cells were replated 24 hours later and exposed to cycloheximide (20 
µg/ml) or MG132 (25 µM), or both, accordingly. Whole cell lysates were prepared 
from the treated cells at the respective times post-treatment for Western blot analysis.  
Lactacystin was used at 10 µM in place of MG132, where appropriate. 
 
4.14 Immunoprecipitation assay (IP) 
In vitro binding reactions for IP were performed by incubating IVT products with p53 
protein in 1X IP buffer at 4oC for 1 hour.   Protein complexes were 
immunoprecipitated using agarose-conjugated antibodies and resolved by SDS-
PAGE, followed by Western blot analysis.  
 
For studying endogenous protein-protein interactions, IP was performed as previously 
described, with modifications [6].  Briefly, transfected cells were washed once with 
1X PBS and then lysed in 250µl of RIPA buffer (20mM Tris-HCl ph7.4, 150mM 
sodium chloride, 1mM EDTA, 1mM dithiothreitol (DTT), 0.5% NP-40 (IGEPAL), 
5mM sodium fluoride and 0.2mM sodium vanadate) at 4oC for 30 mins.  The cells 
were scraped off the plates and then centrifuged (top speed, 1 minute at 4oC) in a 
microfuge tube to remove cell debris.  The supernatant was transferred into a new 
tube and a sample removed for SDS-PAGE analysis (whole cell lysate).  The lysates 
were precleared by addition of 1ml of IP lysis buffer (20mM HEPES, pH 7.4, 200mM 
sodium chloride, 0.05% Tween, 10% glycerol, 1,M EGTA, 1mM DTT, 20mM 
sodium fluoride, 0.1mM sodium vanadate and 10µM zinc chloride) and 50µl of 
Protein A-agarose (Invitrogen catalog no. 15918-014) and incubated with rotation at 
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4oC for at least an hour or overnight.  The lysate supernatants were then transferred 
into new tubes and 50ul of Protein A-agarose, pre-bound with 2µg of the mouse anti-
HA (Santa Cruz) or mouse anti-DP1 Powerclone (Upstate) antibodies, were added to 
each tube of precleared lysate and incubated at 4oC overnight with rotation for 
immunoprecipitation.  The Protein A-agarose beads were pelleted and washed with 
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5. TRIP-Br1 interacts with DP1 and other proteins in vivo. 
5.1 TRIP-Br1 interacts with DP1 in the E2F1/DP1 transcriptional complex in 
vivo. 
It was previously demonstrated that TRIP-Br proteins can interact with DP1 in vitro 
via a GST pull-down assay and that the interaction between TRIP-Br1 and DP1 
(together with E2F1) resulted in transcriptional activation of an E2F-responsive 
promoter [6].  To confirm that TRIP-Br1 and DP1 are components of the same 
transcription complex in vivo, an immunoprecipitation assay with exogenously 
expressed proteins was developed as a model system.  Since endogenous DP1 and 
hTRIP-Br1 interaction was difficult to detect due to the low amounts in almost all 
types of tissue culture cell types7, exogenously expressed DP-1 and HA-tagged 
hTRIP-Br1 were used to visualize the interaction.  U2OS cells were transfected, 
incubated and harvested with IP lysis buffer.  The lysates were pre-cleared and then 
immunoprecipitated with Protein A-agarose bound anti-HA or anti-DP1 monoclonals. 
 
Consistent with previous observations, hTRIP-Br1-HA was able to specifically co-
immunoprecipitate DP1, with and without MG132 treatment (Figure 14 and 15, 
Lanes 5).  It was previously postulated that hTRIP-Br1 interacts with the E2F1/DP1 
transcriptional complex [6].  From the IP analyses, however, E2F1 was not observed 
to be co-immunoprecipitated with hTRIP-Br1-HA, (Figure 14 and 15, lanes 6 and 7).  
Notably, co-expression of E2F1 and E2F1/DP1 was associated with lower hTRIP-
                                                 
7 ML-1 cells are known to express high levels of E2F1 and DP1.  Hsu et al (2001) have previously 
shown that endogenous hTRIP-Br1 co-immunoprecipitates with endogenous DP1. 
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Br1-HA expression levels (Figures 14 and 15, lanes 6 and 7).  Conversely, 
overexpression of DP1 was associated with higher hTRIP-Br1-HA protein levels 
(Figures 14 and 15, lanes 5).  It was consistently observed that exogenous DP1 or 
E2F1 overexpression affects the protein expression levels of co-transfected hTRIP-
Br1-HA, as studied in detail in sections 5.4 and 6.1. 
  
Immunoprecipitations that were done with exogenously co-overexpressed E2F1, DP1 
and hTRIP-Br1-HA showed a clear DP1 co-immunoprecipitation with hTRIP-Br1-
HA (Figures 14 and 15). However, E2F1 co-immunoprecipitation was vague and the 
co-overexpression of E2F1 appeared to diminish the protein amount of co-
overexpressed DP1 and hTRIP-Br1-HA (Figure 14).  Therefore, to maximize protein 
levels, MG132 was added prior to cell harvest (Figure 15). 
 
Addition of MG132 resulted in accumulation of over-expressed proteins, which in 
turn, demonstrated a clearer observation of DP1 co-immunoprecipitation when E2F1 
and DP1 were co-overexpressed.  This was likely to be due to the elevated levels of 
available protein levels for immunoprecipitation.  Another observation noted was the 
appearance of an additional band of higher molecular weight for hTRIP-Br1-HA.  
The presence of this higher molecular weight band was specifically observed with 
MG132 treatment and is discussed in section 6.2. 
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FIGURE 14 DP1 and E2F1 co-immunoprecipitate with hTRIP-Br-
HA pulldown using an anti-HA antibody.   
 
U2OS cells were plated and transfected as described in Materials and Methods.  24 
hours post-transfection, the cells were harvested.  The cell lysates were pre-cleared 
and a 10% sample was taken to run the WCE blot to check for protein expression.  
With the remaining portion of the pre-cleared cell lysates, overnight 
immunoprecipitation was performed with 50 µl of Protein A-agarose bound with 
antibody (2 µg).  The beads were washed and immunoprecipitated proteins analyzed 
by SDS-PAGE and Western immunoblot using anti-E2F1, anti-DP1 and anti-HA 
antibodies. 
All exogenous proteins expressed well (upper panel, WCE).  Endogenous E2F1 and 
DP1 proteins were observed in the WCE probed, respectively.  Exogenous E2F1 and 
DP1 proteins had significantly higher protein amounts.  Anti-HA immunoprecipitated 
hTRIP-Br1-HA (lower panel, lanes 4 to 7), and co-immunoprecipitated DP1 (lower 
panel, lanes 5).  Abbreviations:  WCE (whole cell extract); IP (immunoprecipitation); 
hTB1-HA (hTRIP-Br1-HA). 
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FIGURE 15 DP1 and E2F1 co-immunoprecipitate with hTRIP-Br-
HA pulldown using an anti-HA antibody (MG132).   
 
U2OS cells were plated, transfected and treated with MG132 prior to 
immunoprecipitation, SDS-PAGE and Western blot analyses, as previously 
described.   As previously noted, all exogenous proteins expressed well (upper panel, 
WCE).  Endogenous E2F1 and DP1 proteins were observed in the WCE probed, 
respectively.  Exogenous E2F1 and DP1 proteins had significantly higher protein 
amounts.  Anti-HA immunoprecipitated hTRIP-Br1-HA (lower panel, lanes 4 to 7), 
and co-immunoprecipitated DP1 (lower panel, lanes 5 and 7).  Abbreviations:  WCE 
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5.2 The DP1-binding region of TRIP-Br1. 
To understand an aspect of the physiological relevance of hTRIP-Br1 binding to DP1, 
deletion mutants of hTRIP-Br1-HA were constructed via PCR and tested for binding 
to DP1 by co-immunoprecipitation.  Two groups of deletion mutants were 
constructed: the amino-terminal (N-terminal – ∆12-40, ∆12-50, ∆12-73, ∆12-90 and 
∆12-121) and carboxyl-terminal (C-terminal – 1-222, 1-186 and 1-121) deletion 
mutants.  Each deletion mutant was constructed to remove a putative hTRIP-Br1 
functional domain(s), as previously defined, to determine as a first approximation 
whether the DP1 interaction domain corresponds to a known functional domain 
(Figure 16). 
 
The immunoprecipitation results showed that all the C-terminal deletion mutants of 
hTRIP-Br1-HA were able to co-immunoprecipitate DP1 (Figure 17, lower left panel).  
Similarly, N-terminal deletion mutant ∆12-40 was able to co-immunoprecipitate DP1.  
However, there was a significant loss of the ability for ∆12-73 and ∆12-121 to co-
immunoprecipitate DP1 (Figure 17, lower right pane, lanes 4 and 5).  This suggests 
that there is a region corresponding to the DP1 binding domain on TRIP-Br1 that lies 
between residues 40-121 on hTRIP-Br1, consisting of the heptad repeat, proline, 
serine and threonine rich regions (Figure 16).  The implication from the data, 
however, does not conclusively define the DP1 interaction region and further 
verification such as site directed point mutations and/or testing the interaction with a 
peptide of the deleted residues are required. 
 
54  
Christopher YANG Maolin Yong Loo Lin School of Medicine, NUS 
Ph.D. Thesis  1999-2007 
 
 
In an attempt to further define the DP1 binding region, hTRIP-Br1-HA ∆12-50, ∆12-
60, and ∆12-90 mutants were constructed and similarly tested for DP1 co-
immunoprecipitation.  As demonstrated in Figure 18, the hTRIP-Br1-HA ∆12-50  and 
∆12-90 mutants appear to show a disability to co-immunoprecipitate DP1 (lane 2), 
suggesting that a deletion into the hTRIP-Br1 heptad repeat (lane 2) was possibly 
sufficient to disrupt DP1 interaction.  However, since the protein expression appears 
inadequate, it is also possible that the failure to detect DP1 co-immunoprecipitation 
was a direct result of inadequate hTRIP-Br1-HA binding (or immunoprecipitation). 
Mutant ∆12-60 was not expressed.  Therefore, the results from Figure 18, thus, may 
not provide any significant conclusion. 
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FIGURE 16 Schematic drawing of hTRIP-Br1 domain structure 
and truncation mutants generated.   
The putative domain structures were identified previously [6].  HA-tagged 
deletion/truncation mutants were constructed, by PCR, for further characterization of 
hTRIP-Br1.  C-terminal deletion mutants were constructed with forward and reverse 
primers to a consensus Kozack sequence and the start codon and to the truncation 
points with a HA-tag following the last codon, respectively.  N-terminal deletion 
mutants were constructed using a forward primer that included a consensus Kozack 
sequence continued by the first eleven codons fused to the following sequences after 
the deletion point, as indicated in the schematic.  The heptad repeat has been recently 
classified as the SERTA domain [19, 27]. 
Abbreviations: PCR (Polymerase Chain Reaction); S/T (Serine/Threonine); PHD-
Bromo (Plant Homeodomain-Bromodomain) [6];  
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FIGURE 17 hTRIP-Br1-HA ∆12-73 and ∆12-121 mutants cannot 
co-immunoprecipitate DP1.  
U2OS cells were transfected with pCMV/DP-1 and pcDNA3/hTRIP-Br1-HA (or the 
indicated mutant variants).  Immunoprecipitation assays were performed with cell 
lysates using 2µg of anti-HA antibodies bound to Protein A-agarose beads, as 
described previously.  Precipitated proteins were analyzed by SDS-PAGE and 
Western immunoblot using the respective antibodies.  Protein expression in the WCE 
(upper panels) and immunoprecipitation (lower panels) of hTRIP-Br1 were observed.  
DP-1 co-immunoprecipitation was not observed with hTRIP-Br1-HA ∆12-73 and 
∆12-121 (lower right panel, lane 4 and 5).  It was also noted that hTRIP-Br1-HA 
∆12-73 appeared as a doublet band (right panel, lane 4) 
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FIGURE 18 hTRIP-Br1-HA ∆
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FIGURE 19 hTRIP-Br1-HA and its mutants cannot co-
immunoprecipitate DP1 ∆205-277.  
IP analysis was done as previously described with DP1.   DP1 ∆205-277 co-
immunoprecipitation was not observed even with the hTRIP-Br1-HA wild-type 
control.  Similarly, it was observed that hTRIP-Br1-HA ∆12-73 is represented in the 
Western blot as a doublet band.  DP1 ∆205-277 is well expressed in comparable 
levels in the WCE. 
Abbreviations: WCE (Whole cell extract); IP (immunoprecipitation); WT (wildtype) 
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5.3 The TRIP-Br1 binding region of DP1. 
In addition to its heterodimeric partner E2F1, DP1 has in recent years been 
demonstrated to interact with a number of proteins, such as adenovirus E4, MDM2, 
p14ARF and p53 [12, 16, 36, 40, 44-46, 86, 87].  It was documented that a particular 
DP1 deletion mutant is unable to bind E2F1 [36].  This mutant, DP1 ∆205-277, was 
created and tested for its ability to bind to the various hTRIP-Br1-HA mutants to 
determine the interaction domain on DP1 as well as to confirm the previous 
observations.  The co-immunoprecipitations were carried out as previously done and 
processed by SDS-PAGE and Western immunoblot analyses. 
 
The results showed that there was no detectable co-immunoprecipitation of the DP1 
∆205-277 by any of the deletion mutants or by wild-type hTRIP-Br1-HA although 
DP1 ∆205-277 was expressed (Figure 19).  Therefore, the observation that DP1 
∆205-277 cannot co-immunoprecipitate with hTRIP-Br1-HA (and/or any of the 
mutant variations) strongly suggest that the region 205-277 of DP1 not only contains 
the E2F1 binding domain but also the hTRIP-Br1 binding domain. 
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5.4 Other TRIP-Br1 binding partners – the p53 oncoprotein. 
It was recently reported that p53 and DP1 functionally interact in a manner that is as 
independent of E2F1 binding [44].   Since hTRIP-Br1 interacts closely with DP1, p53 
may also participate in E2F1/DP1/hTRIP-Br1 interaction.  To test this hypothesis, 
U2OS cells were transfected and with various combinations of E2F1, DP1, hTRIP-
Br1-HA and p53, lysates were immunoprecipitated for hTRIP-Br1 and then analyzed 
for co-immunoprecipitation by Western immunoblot.  As expected, DP1 readily co-
immunoprecipitated with hTRIP-Br1-HA, especially without E2F1 co-
overexpression.  With the addition of MG132, DP1 co-immunoprecipitation was 
consistent even with E2F1 co-overexpression, suggesting that the overexpression of 
E2F1 promoted hTRIP-Br1 protein degradation, which MG132 inhibits (discussed in 
a later section).  Furthermore, with MG132 treatment, DP1, E2F1 and p53 co-
immunoprecipitated with hTRIP-Br1-HA indicating that a quaternary complex was 
physiologically formed between these binding partners (Figure 20). 
 
Since p53 had been reported to interact with DP1, it is possible that p53 may affect 
hTRIP-Br1 binding to DP1.  To determine if p53 can compete with hTRIP-Br1 for 
DP1 binding, U2OS cells were transfected with a fixed amount of hTRIP-Br1-HA 
and DP1 and an increasing dose of p53.  DP1 was then immunoprecipitated and the 
extent of hTRIP-Br1 and p53 co-immunoprecipitation observed.  If p53 competed 
with hTRIP-Br1 for DP1 binding, the amount of hTRIP-Br1 co-immunoprecipitated 
would decrease concomitant with the increase in p53 protein levels.  Indeed, with 
increasing p53 expression, a dose-response decrease in hTRIP-Br1-HA co-
immunoprecipitation was observed (Figure 21).  Although this observation suggests 
61  
Christopher YANG Maolin Yong Loo Lin School of Medicine, NUS 
Ph.D. Thesis  1999-2007 
 
 
that p53 has the ability to dominantly compete for DP1 binding, the decrease in the 
total hTRIP-Br1 protein levels in the whole cell extract indicates that the 
mechanism(s) may be more intricate than initially hypothesized.  The simplest 
explanation is that p53 regulates hTRIP-Br1 post-translationally, as addressed in a 
later section.  The other possibility lies with the rapid turnover rate of hTRIP-Br1 
(especially when it is not bound to DP1), such that hTRIP-Br1 that is displaced from 
DP1 by p53 may undergo rapid degradation.  These possibilities, however, do not 
fully account for the observations and a more complex relationship is likely to exist. 
 
In an attempt to prevent the degradation of hTRIP-Br1 from distorting the results, the 
previous experiment was repeated with MG132 treatment (Figure 22, right panel).  As 
previously observed, the amount of p53 co-immunoprecipitated correlated with the 
amount transfected.  However, observed amounts of co-immunoprecipitated hTRIP-
Br1-HA appeared to diminish with increasing p53 although hTRIP-Br1-HA was 
expressed at a similar level throughout.  This observation suggests that p53 binds to 
DP1 and competes with hTRIP-Br1-HA for DP1 binding. 
 
Since DP1 and p53 are known to interact directly, it was tested to determine if 
hTRIP-Br1-HA and p53 also interact directly.  hTRIP-Br1-HA was in vitro 
translated, allowed to bind with purified recombinant p53 and then tested for co-
immunoprecipitation of hTRIP-Br1-HA.  There was no direct interaction detected 
between p53 and hTRIP-Br1-HA as the latter did not co-immunoprecipitate with p53, 
at least under the conditions of this experiment (Figure 23).  However, when hTRIP-
Br1-HA was co-expressed with increasing amounts of p53 and cells were treated with 
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MG132, increasing p53 levels resulted in no (or only slight decrease) change in 
hTRIP-Br1-HA protein levels (Figure 24).  Furthermore, it was observed that p53 co-
immunoprecipitated with hTRIP-Br1-HA in a dose-dependent manner. 
 
5.5 Other TRIP-Br1 binding partners – the E6 oncoprotein. 
It was  reported by Gupta et al (2003) [24] that hTRIP-Br1 interacted with the Human 
Papillomavirus E6 oncoprotein.  In a collaborative effort, the functional consequence 
of this interaction was investigated and the results discussed later in Section 8.3. 
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FIGURE 20 E2F1, DP1, hTRIP-Br1-HA and p53 are co-
immunoprecipitation with hTRIP-Br1-HA in a 
quaternary complex with MG132 treatment.  
U2OS cells were transfected with pCMV/E2F-1, pCMV/DP-1, pCMV/p53 and 
pcDNA3/hTRIP-Br1-HA and immunoprecipitation assays performed using 2 µg of 
anti-HA antibodies bound to Protein A-agarose beads, as described in Materials and 
Methods.  Precipitated proteins were analyzed by SDS-PAGE and Western 
immunoblot using anti-E2F1, anti-DP1, anti-p53 and anti-HA antibodies.  Protein 
expression (upper panels, WCE) and (co-)immunoprecipitation (lower panels, IP) 
profiles were observed.   
Endogenous levels of E2F1, DP1 and p53 were detected in the WCE immunoblot and 
exogenous expressions of the respective proteins were observed by significantly 
larger band intensities.  E2F1, DP1, p53 and hTRIP-Br1 were immunoprecipitated as 
a quaternary complex in vivo and visualization was enhanced with MG132 treatment 
for 4 hours prior to harvest of cell lysates (right half of panel, lanes 5-9). 
Abbreviations: WCE (Whole cell extract); IP (immunoprecipitation); hTB1-HA 
(hTRIP-Br1-HA); (m) (mouse monoclonal antibody); (r) (rabbit polyclonal antibody) 
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FIGURE 21 Co-expression of p53 affects the expressed levels of 
hTRIP-Br1-HA.  
U2OS cells were transfected with pCMV/DP-1, pCMV/p53 (0.05µg to 0.4µg range) 
and pcDNA3/hTRIP-Br1-HA and immunoprecipitation assays performed using 2 µg 
of anti-DP1 and subsequently analyzed by SDS-PAGE/Western immunoblot using 
anti-DP1, anti-p53 and anti-HA antibodies as described. Protein expression (upper 
panels, WCE) and (co-) immunoprecipitation (lower panels, IP) profiles were 
observed.  Both hTRIP-Br1-HA and p53 co-immunoprecipitated with DP1.  
Increasing expression levels of p53 resulted in diminishing amounts of hTRIP-Br1-
HA in both whole cell extract and immunoprecipitated samples, indicating that IP 
observations were affected by starting protein levels and therefore not comparable. 
Abbreviations: WCE (Whole cell extract); IP (immunoprecipitation); (m) (mouse 
monoclonal antibody); (r) (rabbit polyclonal antibody) 
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FIGURE 22 Co-expression of p53 affects the interaction of hTRIP-
Br1-HA with DP1 (in the presence of MG132). 
U2OS cells were transfected with pCMV/DP1, pcDNA3/hTRIP-Br1-HA and 
increasing doses of pCMV/p53 (0.1µg to 0.5µg).  Half of the cells were treated with 
25µM MG132 for 4 hours prior to cell lysate harvest.  Immunoprecipitation assays 
were performed using 2 µg of anti-DP1 monoclonal antibodies bound to Protein A-
agarose beads, and subsequently analyzed by SDS-PAGE/Western immunoblot using 
anti-DP1, anti-p53 and anti-HA antibodies as described.  Protein expression (upper 
panels, WCE) and (co-) immunoprecipitation (lower panels, IP) profiles were 
observed.  Without MG132 treatment, increasing p53 protein levels had an inverse 
relationship to hTRIP-Br1-HA protein levels (WCE left panel).  However, with 
MG132 treatment, hTRIP-Br1-HA protein levels were consistent and the 
corresponding IP profile comparable.  Both hTRIP-Br1-HA and p53 were co-
immunoprecipitated with DP1.  However, increasing p53 protein levels resulted in 
diminishing amounts of co-immunoprecipitated hTRIP-Br1-HA indicating a 
competitive interaction with DP1. 
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FIGURE 23 p53 does not interact directly with hTRIP-Br1-HA in 
vitro.  
pcDNA3/hTRIP-Br1-HA was in vitro translated using the Rabbit Reticulocyte TnT 
T7 in vitro translation kit (Promega), as described in Materials and Methods, and 
tested for direct interaction with commercially purified recombinant p53 by in vitro 
pull down with Protein A agarose bound with 2µg anti-p53 antibody.  p53 was readily 
immunoprecipitated but no direct interaction was observed between hTRIP-Br1-HA 
and p53, based on absence of co-immunoprecipitation of hTRIP-Br1-HA (lanes 4 to 
6). 
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FIGURE 24 p53 co-immunoprecipitation with hTRIP-Br1-HA is 
observed with MG132 treatment.  
U2OS cells were transfected with pcDNA3/hTRIP-Br1-HA and an increasing dose of 
pCMV/p53  (0.1µg to 0.5µg) and then subjected to 25µM MG132 treatment for 4 
hours.  Immunoprecipitation assays were performed using 2 µg of anti-HA polyclonal 
antibodies bound to Protein A-agarose beads, and subsequently analyzed by SDS-
PAGE/Western immunoblot using anti-p53 and anti-HA antibodies as described.  
Protein expression (upper panels, WCE) and immunoprecipitation (lower panels, IP) 
profiles were observed.   
The expression of p53 and hTRIP-Br1 were as expected except that hTRIP-Br1-HA 
protein levels were visibly lower with the highest p53 co-expression.  Furthermore, 
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6. TRIP-Br1 is regulated post-translationally and degraded via the 26S 
proteosomal pathway 
6.1 TRIP-Br1 is regulated by degradation, and is affected by DP1 
overexpression 
It was previously observed that hTRIP-Br1-HA protein levels appeared to be higher 
when co-expressed with DP1 (Figure 14, compare lanes 2 and 5).  This observation 
suggests that either hTRIP-Br1-HA protein expression is up-regulated or that the 
protein is being degraded at a slower rate, giving rise to higher protein expression 
levels.  To differentiate between the two possibilities, cycloheximide (CHX) 
treatment was employed.  Upon addition of the cell membrane permeable protein 
synthesis inhibitor, cycloheximide, protein production in the cell is inhibited at the 
ribosomal P/A catalytic site resulting in inhibition of de novo protein synthesis.  The 
existing protein levels would be expected to degrade over time depending on protein 
half-life.  U2OS cells were transfected with hTRIP-Br1-HA with or without DP1 co-
transfection.  The transfected cells were re-plated 24 hours post-transfection.  
Twenty-four hours later, the cells were treated with cycloheximide for a range of time 
period and whole cell lysates harvested for analysis by SDS-PAGE and Western 
immunoblot. 
 
In vector-transfected cells, no HA-tagged hTRIP-Br1 was detected (Figure 25, upper 
panel).  hTRIP-Br1-HA had a relatively short half-life of about 20-30 minutes and 
was not detectable by 60 minutes post-CHX treatment (Figure 25, middle panel).  
Endogenous DP1 appeared to have a relatively slow turnover rate, as DP1 protein 
levels remained persistent beyond 480 minutes.  Notably, overexpression of 
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exogenous DP1 was associated with a dramatically increased protein half-life for 
hTRIP-Br1-HA, with protein levels persisting well beyond 240 minutes (Figure 25, 
lower panel). 
 
To observe the effects in the physiological context of overexpression of both E2F1 
and DP1 heterodimers, cycloheximide treatment was repeated on cells transfected 
with various combinations of hTRIP-Br1-HA, E2F1 and DP1 (Figure 26).  Whole cell 
lysate was obtained after cycloheximide treatment (hourly from 0-4 hours) and 
analyzed by SDS-PAGE and Western immunoblot.  The blots were then detected 
with anti-HA for hTRIP-Br1, anti-cdk2 as an internal control and anti-CycD1 as a 
non-specific control.  When E2F1 and DP1 were both overexpressed, hTRIP-Br1 
protein levels were reduced to less than 10% within one hour (Figure 26 Panel A).  
Furthermore, with E2F1 co-expression, initial hTRIP-Br1 protein levels appeared to 
be about 50% as compared to hTRIP-Br1 alone.  Conversely, with DP1 co-
expression, hTRIP-Br1 protein levels decreased marginally and persisted beyond 4 
hours.  Cdk2 levels were consistent throughout the treatment and cyclin D1 levels 
showed no significant change in degradation, demonstrating comparable loading and 
presence of a functional (proteosomal) degradation pathway. 
 
To rule out the possibility of the protein accumulation due to a lack of mRNA 
degradation, semi-quantitative Reverse-Transcriptase PCR (RT-PCR) was done to 
determine the mRNA levels of hTRIP-Br1.  The results show that there was an 
expected increase in TRIP-Br1 mRNA in cells transfected with hTRIP-Br1-HA, and 
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there was no significant difference in mRNA levels in samples observed to have 
variations in protein turnover (Figure 26 Panel B).  
 
To determine the specificity of the observed DP1 post-translational regulatory effect 
on hTRIP-Br1-HA, similar experiments were carried out in which transfected DP1 
and E2F1 were varied in an increasing dose  hTRIP-Br1-HA was observed to have a 
concomitant increase in half-life with increasing dose of transfected DP1 (Figure 27 
A).  Conversely, hTRIP-Br1-HA protein levels were initially lowered with E2F1 co-
overexpression. (Figure 27 B).  Increasing co-overexpression of E2F1 resulted in 
decreasing hTRIP-Br1-HA protein levels at the beginning of CHX treatment.  This 
observation strongly suggests that exogenous E2F1 overexpression promotes hTRIP-
Br1 degradation. 
 
Since it has been established that hTRIP-Br1 and DP1 physiologically interact, and 
that DP1 appears to regulate hTRIP-Br1 via a post-translational mechanism, the next 
question is whether the above observed regulation is dependent on DP1 interaction.  
Towards answering this question, hTRIP-Br1-HA deletion mutants were used in 
similar assays to establish their degradation profiles in the presence of exogenously 
overexpressed DP1.  All the C-terminal deletion mutants and ∆12-121 had a shorter 
half-life as compared to wild-type hTRIP-Br1 (Figure 28).  The other N-terminal 
mutants displayed a more varied outcome.  ∆12-40 degraded significantly faster than 
wild-type hTRIP-Br1 whilst ∆12-73 protein levels persisted beyond 60 minutes.
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FIGURE 25 hTRIP-Br1-HA protein stability is increased by DP-1 
overexpression.  
 
U2OS cells were co-transfected with pcDNA3/hTRIP-Br1-HA and pCMV/DP1 or 
vector and subjected to cycloheximide (CHX) treatment for the indicated times.  
Samples were harvested with SDS Loading buffer and subsequently analyzed by 
SDS-PAGE/Western immunoblot using anti-DP1, anti-HA and anti-Cdk2.  hTRIP-
Br1-HA degradation was observed over 20-30minutes and was undetectable by 60 
minutes  However, when exogenous DP1 was co-expressed, hTRIP-Br1-HA did not 
significantly degrade over the same time period, and had detectable protein levels at 4 
hours post-CHX treatment. 
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FIGURE 26 hTRIP-Br1 protein stability is influenced by DP-1 
and/or E2F-1 overexpression.   
A) hTRIP-Br1-HA was co-transfected with pCMV/DP-1 and/or pCMV/E2F-1 
accordingly, CHX added and whole cell lysate harvested at the indicated times.  SDS-
PAGE and Western immunoblot analyses were performed.  hTRIP-Br1-HA levels 
were maintained with DP-1 co-overexpression alone, in a dose-dependent manner.  
Conversely, hTRIP-Br1 levels were diminished with E2F-1 co-overexpression alone.   
B) RT-PCR was done on samples treated with CHX for 4 hours, as described in 
Materials and Methods, to determine if protein accumulation observed was due to 
accumulation of mRNA.  Endogenous hTRIP-Br1 mRNA were expressed (lanes 1-4), 
while superimposed exogenously hTRIP-Br1-HA mRNA was overexpressed (lanes 5-
8) at comparable levels independent of co-overexpression E2F1 and/or DP1,which 
did not correlate with changes in protein levels as demonstrated in the corresponding 
Western immunoblots. 
Abbreviations: RT-PCR (Reverse-transcriptase Polymerase Chain Reaction); hTB1-
HA (hTRIP-Br1-HA); CHX (Cycloheximide) 
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FIGURE 27 hTRIP-Br1 protein stability is specifically affected by 
DP1 and E2F1 overexpression in a dose-dependent 
manner.   
 
U2OS cells were transfected with hTRIP-Br1-HA and co-transfected with increasing 
doses of pCMV/DP1 or pCMV/E2F1 accordingly, CHX was added and the whole 
cell lysate harvested at the indicated times.  SDS-PAGE and Western immunoblot 
analyses were performed as described.   
A)  Dose-dependent overexpression of DP1 was associated with corresponding 
increases in hTRIP-Br1-HA stability. 
B)  Dose-dependent overexpression of E2F1 was associated with corresponding 
decreases in hTRIP-Br1-HA stability. 
Abbreviation: WB (Western immunoblot) ; CHX (cycloheximide) 
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FIGURE 28 hTRIP-Br1 deletion mutants exhibit differences in 
protein stability when co-overexpressed with DP1. 
U2OS cells were transfected with pCMV/DP1 and pcDNA3/hTRIP-Br1-HA (WT and 
the various constructed mutants), treated with CHX and whole cell lysates harvested 
at the indicated times.  SDS-PAGE and Western immunoblot analyses were 
performed, as described in Materials and Methods.  Wild-type hTRIP-Br1-HA had a 
slow turnover, with protein levels visibly persisting over 60 minutes.  Furthermore, 
there was an extra higher molecular weight band when hTRIP-Br1-HA was co-
overexpressed with DP1, as noted previously.  The C-terminal truncation mutants (1-
222, 1-186 and 1-121) appeared to have a similar or slightly shorter half-life when 
compared to wild-type hTRIP-Br1-HA.  The N-terminal deletion mutants had varied 
half-lives; ∆12-40 was rapidly degraded lasting less than 10 minutes, ∆12-73 did not 
significantly degrade during the course of the experiment, and ∆12-121 had a shorter 
half-life as compared to wild-type with protein levels that were undetectable after 45 
minutes of CHX treatment.  The hTRIP-Br1-HA ∆12-73 mutant was again noted to 
be expressed as doublet bands. DP1 was well-expressed and Cdk2 was detected as an 
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6.2 TRIP-Br1 is degraded via the 26S proteosomal pathway. 
Since it was established that hTRIP-Br1 was post-translationally regulated, the 
mechanism of its degradation was therefore investigated further.  The 26S 
proteosomal pathway is by far the best known and widely used mechanism for 
cellular protein turnover [88].  Specific inhibitors of the 26S proteosome are available 
and these include compounds such as MG132 [89, 90] and lactacystin [91-93].  
Treatment with these inhibitors hinder proteolysis of proteins marked for degradation 
by the 26S proteosome, and would lead to their accumulation and an increase in their 
steady-state levels. Therefore, the previous experiment was repeated in a similar 
manner after the cells were treated with MG132 for up to 8 hours instead. 
 
As shown in Figure 29, DP1 protein levels predictably accumulated over time since 
DP1 is known to be degraded via the 26S proteosomal pathway [47].  Similarly, 
hTRIP-Br1-HA protein levels accumulated with MG132 treatment, indicating that 
hTRIP-Br1-HA is degraded via the 26S proteosomal pathway.  E2F1 co-
overexpression led to a slightly slower rate of hTRIP-Br1-HA accumulation, 
suggesting that E2F1 may be promote hTRIP-Br1-HA degradation even with MG132 
treatment, an observation consistent with previous results.  Conversely, DP1 co-
overexpression led to increased hTRIP-Br1-HA accumulation.  This suggests that 
direct binding of DP1 to hTRIP-Br1-HA may inhibit its degradation, resulting in the 
steady-state accumulation of the hTRIP-Br1-HA. 
 
In the literature, there was a growing concern that using MG132 may not be a specific 
inhibitor for the 26S proteosomal degradation pathway as initially believed.  
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Therefore, lactacystin, a highly specific 26S proteosome inhibitor was used to 
confirm previous results employing MG132 to demonstrate that hTRIP-Br1-HA is 
degraded specifically through the 26S proteosomal pathway.  The results in Figure 30 
show that both MG132 and lactacystin inhibit hTRIP-Br1-HA degradation, resulting 
in an accumulation of hTRIP-Br1-HA protein levels in cells.  Notably, accumulation 
was slower with lactacystin, consistent with the requirement for metabolism of this 
compound to an active inhibitory molecule [91-93]. 
 
6.3 TRIP-Br1 is regulated post-translationally by p53. 
It was determined through earlier immunoprecipitation assays that p53 was part of a 
quaternary complex that included E2F1, DP1 and hTRIP-Br1-HA.  It was also 
observed in previous experiments that co-overexpression of increasing amounts of 
p53 resulted in correspondingly lower hTRIP-Br1-HA steady-state protein levels.  In 
addition, it was necessary for the immunoprecipitation assays to employ the use of 
MG132, a 26S proteosomal inhibitor, to stabilize the protein levels for analysis.  This 
observation strongly suggests that p53 may be involved in the post-translational 
regulation of hTRIP-Br1. 
 
To determine the magnitude of p53 involvement in the post-translational regulation of 
hTRIP-Br1-HA steady-state levels, p53 was co-transfected with DP1 and hTRIP-Br1-
HA.  The cells were treated with CHX as previously described and whole cell lysates 
harvested for SDS-PAGE/Western immunoblot analysis with anti-HA and anti-Cdk2 
(internal loading control).  In vector-transfected cells, p53 levels were undetectable 20 
minutes after cycloheximide treatment (Figure 31).  Furthermore, hTRIP-Br1-HA 
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turnover with or without DP1 co-overexpression was as previously observed.  When 
p53 was co-transfected with hTRIP-Br1-HA and DP1, the ability of DP1 to prevent 
hTRIP-Br1-HA degradation was abolished.  p53 co-overexpression resulted in a 
faster hTRIP-Br1-HA degradation rate, with protein levels undetectable by 20 
minutes, as compared to 30 minutes for hTRIP-Br1-HA alone.  Furthermore, by 
comparing the initial levels of hTRIP-Br1-HA at time 0 post-cycloheximide 
treatment, it was apparent that p53 co-overexpression resulted in significantly lower 
hTRIP-Br1-HA at time 0.  The results indicate that p53 co-overexpression not only to 
abrogates the effects of DP1 ‘protection’ of hTRIP-Br1-HA from degradation but also 
accelerates the degradation of hTRIP-Br1-HA, either by one of two mechanisms:  1) 
by affecting the overall levels of hTRIP-Br1-HA (i.e. initial expression levels were 
lower as compared to hTRIP-BR1-HA overexpression alone); or 2) by directly 
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FIGURE 29 hTRIP-Br1 is degraded by the 26S proteosomal 
pathway. 
 
U2OS cells were transfected accordingly, treated with 25 µM MG132 as indicated 
and whole cell lysates harvested.  SDS-PAGE and Western immunoblot analyses 
were performed with anti-DP1, anti-HA and anti-Cdk2 (loading control), as described 
in Materials and Methods.  Accumulation of hTRIP-Br1-HA was observed with 
MG132 treatment after 2 hours.  DP-1 co-overexpression resulted in a higher initial 
hTRIP-Br1-HA expression levels and an earlier accumulation uponMG132 treatment.  
The converse was observed in the case of E2F-1 co-overexpression. 
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FIGURE 30 hTRIP-Br1-HA degradation is inhibited by the 26S 
proteosome inhibitors MG132 and Lactacystin. 
U2OS cells were transfected with hTRIP-Br1-HA, treated with 25µM MG132 or 
lactacystin as indicated and whole cell lysates harvested.  SDS-PAGE and Western 
immunoblot analyses were performed with anti-HA and anti-Cdk2 (loading control), 
as described in Materials and Methods.  Accumulation of hTRIP-Br1-HA was 
observed with MG132 and lactacystin treatment after 2 hours, although the latter 
appeared to be slower in inducing hTRIP-Br1-HA protein accumulation. 
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FIGURE 31 Co-overexpression of p53 is associated with more 
rapid hTRIP-Br1-HA degradation. 
 
U2OS cells were transfected with pcDNA3/hTRIP-Br1-HA, pCMV/DP1 and 
pCMV/p53, treated with 20µg/ml CHX as indicated and whole cell lysates harvested.  
SDS-PAGE and Western immunoblot analyses were performed with anti-HA and 
anti-Cdk2 (loading control), as described in Materials and Methods, to determine the 
half-life of hTRIP-Br1-HA proteins.  Top panel showed that p53 was expressed and 
had a relatively fast turnover of approximately 15-20 minutes.  Cdk2 was detected as 
an internal loading control.  The hTRIP-Br1-HA half-life was approximately 30 
minutes, as previously determined (second from top panel).  Co-overexpression of 
DP1 resulted in hTRIP-Br1-HA degrading at a significantly degradation rate for 
hTRIP-Br1-HA, with protein levels persisting beyond 60 minutes (second from 
bottom panel).  Co-overexpression of both DP1 and p53 together with hTRIP-Br1-







Christopher YANG Maolin Yong Loo Lin School of Medicine, NUS 
Ph.D. Thesis  1999-2007 
 
 
6.4 Putative post-translational modification of TRIP-Br1. 
It was observed that there was a specific higher molecular weight (MW) band 
whenever the hTRIP-Br1-HA degradation was prolonged, as in the case of DP1 co-
overexpression.  Furthermore, observations with CHX and MG132 treatment strongly 
suggested that it was likely for hTRIP-Br1-HA to undergo some form of post-
translational modification.  The presence of the upper band was observed and its 
intensity enhanced with increasing DP1 co-overexpression (Figure 27) and when cells 
expressing hTRIP-Br1-HA were treated with MG132 or lactacystin.  Furthermore, 
overexpression of the hTRIP-Br1-HA ∆12-73 mutant, which was independently 
stable and had a persistent protein level despite cycloheximide treatment, was also 
associated with overexpression of a high MW band as intense as the wild-type 
hTRIP-Br1-HA band on an immunoblot. 
 
The post-translational modifications that mark proteins for degradation are commonly 
phosphorylation, acetylation, ubiquitination and SUMOylation.  In the previous 
experiments, treatments or conditions that increased the accumulation of hTRIP-Br1-
HA and its higher MW form(s) likely reflect mechanisms that prevent post-
translationally modified proteins from undergoing degradation.  The observed 
possible post-translational modification was not conclusively defined and is discussed 
in a later chapter. 
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7. TRIP-Br1 is a nuclear protein and co-localizes DP1 via its interaction. 
7.1 TRIP-Br1 is a nuclear protein that aids in the co-localization of DP1. 
Thus far, it has been ascertained that hTRIP-Br1 interacts with DP1 and hTRIP-Br1 
degradation is hampered as a result of this interaction.  Another aspect for 
physiological function to consider is whether the interaction between hTRIP-Br1 and 
DP1 results in any changes to the localization of either of the two proteins.  It was 
expected that there would be changes to localization patterns since previous results 
with DP1 interaction changed the degradation pattern of hTRIP-Br1.  Confocal 
microscopy was done on U2OS cells transfected with hTRIP-Br1-HA and/or T7-
tagged DP1.  The cells were fixed and visualization was aided with the use of 
fluorophore labeled antibodies against each tag (HA or T7 tag). 
 
In cells overexpressing hTRIP-Br1-HA, the anti-HA specifically detected the 
exogenously expressed protein concentrated within the nucleus (Figure 32, top panel).  
This observation confirms that hTRIP-Br1 is indeed a nuclear protein.  Detection with 
anti-T7 on T7-DP1 transfected cells showed a diffuse distribution of T7-DP1 proteins 
throughout the cell suggesting that DP1 is unable to localize within the nucleus 
(Figure 32, middle panel).  This observation is consistent with literature reports that 
DP1 lacks a nuclear localization signal and is unable to transport itself in to the 
nucleus (without E2F facilitation) [36, 47].  When T7-DP1 was co-overexpressed 
with hTRIP-Br1-HA, T7-DP1 was observed to co-localize with hTRIP-Br1 in the 
nucleus (Figure 32, lower panel).  This demonstrates that the physiological relevance 
of the interaction between DP1 and hTRIP-Br1 that results in co-localization of DP1 
with hTRIP-Br1 within the nucleus. 
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The hTRIP-Br1-HA truncation mutants were also tested for both hTRIP-Br1-HA 
nuclear localization as well as the DP1 co-localization.  Figure 33 demonstrates that 
the C-terminal deletion mutants tested retained their nuclear protein properties.  
Deletion of the C-terminal half of hTRIP-Br1-HA imposed no significant effects to 
the intracellular localization of the mutants.  The hTRIP-Br1-HA N-terminal deletion 
mutants, however, appeared to have a slight impairment to the nuclear localization 
(Figure 34, ∆12-50 to ∆12-121), with ∆12-40 being slightly “leaky”.  This 
phenomenon was observed despite the presence of the putative NLS present in the 
first 12 residues of hTRIP-Br1-HA in all the N-terminal truncation mutants.  Since 
hTRIP-Br1-HA ∆12-40 showed no significant difference in nuclear localization, as 
compared to hTRIP-Br1-HA (Figure 34, extreme column anti-HA), the apparent 
disability of the other N-terminal deletion mutants to localize in the nucleus is likely 
due to the absence of the deleted segment.   
 
It was previously observed that the N-terminal mutants had a variety of responses to 
DP1 co-immunoprecipitation and protein stability.  Therefore, the N-terminal mutants 
were tested for their ability to co-localize co-overexpressed T7-DP1.  It was observed 
that DP1 was unable to co-localize in the nucleus with the hTRIP-Br1-HA N-terminal 
deletion mutants to varying extents, as compared to wild-type.  With progressive N-
terminal deletions, a deterioration in the hTRIP-Br1-HA ability to promote co-
localization of DP1 was observed (Figure 34, second and third column; anti-T7 and 
overlap).  These observations are consistent with the data presented in previous 
sections and suggests that the inability of T7-DP1 and hTRIP-Br1-HA to interact 
affects DP1 intracellular localization. 
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FIGURE 32 hTRIP-Br1 proteins are nuclear proteins that aid in 
DP-1 co-localization into the nucleus.   
 
U2OS cells plated on glass cover slip slides, were transfected with pcDNA3/hTRIP-
Br1-HA and/or pcDNA3/T7-DP1.  The cells were processed for confocal microscopy 
as described in the Materials and Methods.  Briefly, the cells were fixed with 4% 
paraformaldehyde, permeabilized with Triton X-100 and then detected with anti-HA 
(for hTRIP-Br1-HA) or anti-T7 (for T7-DP1).  Cells were visualized by fluorescence 
confocal microscopy.  hTRIP-Br1-HA was detected almost exclusively within the 
nucleus (green) but T7-DP1 alone was spread throughout the cell (red).   In 
overlapping exposures with anti-HA (hTRIP-B1-HA, green) and anti-T7 (DP-1, red), 
it appears that the pattern of DP1 distribution mimics that of hTRIP-Br1-HA 
suggesting that T7-DP1 co-localizes with hTRIP-Br1-HA in the nucleus (yellow).  
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FIGURE 33 hTRIP-Br1-HA C-terminal truncation mutant 
proteins retain the ability to localize in the nucleus.   
 
U2OS cells plated on glass cover slip slides, were transfected with pcDNA3/hTRIP-
Br1-HA or the mutants indicated.  The cells were prepared for confocal microscopy 
as described previously.  The hTRIP-Br1 C-terminal truncation mutants retained the 
ability to localize in the nucleus. 
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FIGURE 34 Intracellular localization of the hTRIP-Br1-HA N-
terminal truncation mutant proteins. 
 
U2OS cells plated on glass cover slips were co-transfected with pcDNA3/hTRIP-Br1-
HA (and/or the mutants) and pCMV/T7-DP1 as indicated.  The cells were prepared 
for confocal microscopy as described previously.  The hTRIP-Br1 N-terminal 
truncation mutants were observed to be less localized within the nucleus with each 
mutant that had a larger N-terminal region deleted (∆12-40 to ∆12-121).  DP1 alone 
was observed to be both nuclear and cytoplasmic (DP1).  Its nuclear localization was 
well-defined and co-localized with co-overexpressed hTRIP-Br1-HA within the 
nucleus (hTB1-HA + DP1).  However, when co-overexpressed with the hTRIP-Br1-
HA N-terminal truncation mutants, DP1 was observed not to co-localize into the 
nucleus and was more cytoplasmic (∆12-40 to ∆12-121 + DP1). 
Abbreviations: hTB1 — hTRIP-Br1-HA, ∆12-40 — hTRIP-Br1-HA ∆12-40, etc.,  
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8. TRIP-Br1 is a transcriptional co-regulator of the E2F1/DP1 transcription 
complex 
8.1 TRIP-Br1 and mutant co-activation of the E2F1/DP1 transcriptional 
regulator complex 
It was previously reported that TRIP-Br1 up-regulates transcriptional activity through 
interaction with the E2F1/DP1 transcriptional regulator complex [6, 22].  The hTRIP-
Br1 mutants were tested for transcriptional activity on a 6XE2F luciferase reporter 
construct.  Figure 35 shows the effects of the hTRIP-Br1 mutants on the E2F1/DP1 
complex transcriptional activity.  It was demonstrated that hTRIP-Br1-HA (WT) had 
the ability to increase the transcriptional activity of the E2F1/DP1 heterodimer on a 
heterologous E2F-responsive promoter by almost 25%.  Deletion of the last 14 amino 
diminished the transcriptional augmentation achieved with wild-type hTRIP-Br1-HA.  
Further C-terminal deletions resulted in the repression of E2F1/DP1 transcriptional 
activity instead (mutants 1-186 and 1-121). 
 
The first 11 residues of hTRIP-Br1 were postulated to contain a nuclear localization 
signal [6, 22].  In order to confirm this hypothesis, N-terminal deletion mutants, 
starting from the 12th residue, were constructed.  Mutant ∆12-40 exhibited no 
transcriptional co-activation, while ∆12-50 and ∆12-121 did not differ significantly 
from wild-type with respect to transcriptional co-activation function.  Notably, ∆12-
73 and ∆12-90 both exhibited increased transcriptional co-activation of an E2F-
responsive heterologous reporter (two-fold higher than wild-type).  This suggests the 
presence of a novel transcriptional repression domain that was affected by the 
removal of residues 12-73. 
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8.2 A single residue conservative mutation is able to increase hTRIP-Br1 
transcriptional activation in conjunction with E2F1/DP1 heterodimeric 
complex 
From previous observations, it was postulated that the function of hTRIP-Br1 may be 
post-translationally regulated and a possible mechanism was through the addition of 
biochemical groups.  One such post-translational modification is the acetylation of 
proteins, by which an acetyl group is added onto the epsilon amino group of lysine 
residues, to affect the activity of a protein.  Besides the N-terminal lysine residues in 
the putative nuclear localization signal of hTRIP-Br1, there were 3 other potential 
lysine residues as acetyl acceptor sites, namely, K52, K195 and K204.  Site directed 
mutagenesis was performed to construct conservative single lysine to arginine 
(KÆR) mutants, hTRIP-Br1-HA K52R, K195R or K204R.  A single lysine to 
arginine mutation is a conservative mutation that preserves the structural integrity of 
the overall protein, except that the acceptor site for the acetyl group is now absent.  
Therefore, the construction of these mutants allows investigations on the activities of 
the mutant protein without the post-translational modification. 
 
The conservative single residue mutants were assayed for their transcriptional activity 
on the E2F-responsive heterologous reporter system as described in the previous 
section.  Wild-type hTRIP-Br1-HA was again observed to co-activate the 
transcriptional activity of the E2F1/DP1 heterodimeric complex.  Mutant K52R and 
the triple mutant K52,195,204R exhibited a significant increase in transcriptional co-
activation compared to wild-type hTRIP-Br1-HA, with the triple mutant having a 
higher readout than the single mutant (Figure 36). A single conservative mutation 
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from KÆR at residue 52 was sufficient to bring about transcriptional co-activation 
that is higher than the wild-type.  In conjunction with two other KÆR mutations at 
residues 195 and 204, the triple mutant further enhanced the transcriptional co-
activation of the E2F1/DP1/hTRIP-Br1 complex.  This result indicates that the lysine 
residues may be post-translationally modified and the modifications appear to 
moderate the transcriptional activity of hTRIP-Br1. 
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FIGURE 35 In vitro transcriptional assay of hTRIP-Br1-HA on a 
6XE2F responsive luciferase reporter. 
 
COS7 cells were plated in 24-well plates and transfected accordingly.  Lysates were 
prepared and analyzed for luciferase activity, as per manufacturer’s instructions for 
the Dual Luciferase Assay.  Fold activation increased with co-expression of hTRIP-
Br1-HA with E2F1 and DP1.  C-terminal mutants, however, had a reduction in 
transcriptional activation.  N-terminal mutants exhibited a variety of responses with 
hTRIP-Br1-HA ∆12-73 and ∆12-90 effecting a transcriptional activity which was 
significantly higher than wild-type hTRIP-Br1-HA on E2F1/DP1. 
The results were obtained from 3 independent experiments of triplicates. 
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FIGURE 36 In vitro transcriptional assay of hTRIP-Br1-HA site-
directed mutants on a 6XE2F responsive luciferase 
reporter. 
 
COS7 cells were plated in 24-well plates and transfected accordingly.  Lysates were 
prepared and analyzed for luciferase activity, as per manufacturer’s instructions for 
the Dual Luciferase Assay.  Fold activation increased slightly with the KÆR mutants 
without E2F1/DP1 co-expression, likely to be acting upon the endogenous levels of 
E2F1 and DP1. With E2F1 and DP1 co-expression, hTRIP-Br1-HA augmented the 
transcriptional activation significantly higher than E2F1/DP1 alone.  The K52R 
mutant further augmented the transcriptional activity and the K52,195,204R mutant 
demonstrated the highest transcriptional activity. 
The results were obtained from 3 independent experiments of triplicates. 
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8.3 The E2F1/DP1/TRIP-Br1 transcriptional complex is further co-activated 
by HPV E6 oncoprotein 
It was reported in Gupta et al (2003) [24], that the E2F1/DP1/hTRIP-Br1 could 
interact with the human papillomavirus (HPV) E6 oncoprotein.  It was first 
discovered that TRIP-Br1 could interact with the E6 oncoprotein as it was pulled-
down in a yeast-two-hybrid assay designed to identify proteins interacting with E6.  
In a collaborative effort, the functional aspect of the interaction was determined 
through an in vitro transcriptional assay optimized to reconstruct the E2F1/DP1 
complex on an E2F-responsive promoter.  E6 oncoproteins were co-expressed with 
E2F1/DP1 and/or hTRIP-Br1-HA and the transcriptional readouts determined through 
a dual luciferase assay.  It was determined that HPV E6, not only had the ability to 
augment the transcriptional activity of E2F1/DP1 and hTRIP-Br1-HA separately, but 
it was also able to co-activate the E2F1/DP1/hTRIP-Br1 transcriptional complex at 
least 5-fold over the E2F1/DP1 activity (Figure 37).  From these observations, it 
appears that HPV E6 is a co-regulator that is recruited by its interaction with hTRIP-
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FIGURE 37 In vitro transcriptional assay of the Human 
Papillomavirus (HPV) E6 oncoprotein effects on 
E2F1/DP1/hTRIP-Br1-HA transcriptional activity, 
using a 6XE2F responsive Luciferase reporter. 
 
COS7 cells were plated in 24-well plates and transfected as indicated with 2ng E2F1, 
2ng DP1, 750ng hTRIP-Br1-HA, and/or 350ng 11-/16-E6.  Lysates were prepared 
and analyzed for luciferase activity, as per manufacturer’s instructions for the Dual 
Luciferase Assay.  Fold activation increased slightly with E6 expression.  Co-
expression of hTRIP-Br1-HA and E6 effected a response greater than E2F1/DP1 
itself (lanes 5,6 versus lane 7).  E6 alone augments E2F1/DP1 transcriptional 
activation.  The co-overexpression of E6 together with hTRIP-Br1-HAis associated 
with 5-fold increase in the transcriptional readout compared to E2F1/DP1 alone. 
The results were obtained from 3 independent experiments of triplicates. 
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Hsu et. al. had previously proposed the Integrator Model (Figure 7) whereby TRIP-Br 
proteins function as transcriptional co-regulators to mediate the signals between non-
DNA binding transcriptional regulators and the DNA-binding E2F1/DP1 heterodimer 
complex [6, 22, 94].  In that paper, TRIP-Br proteins were shown to act as 
transcriptional activators and observed to co-immunoprecipitate with endogenous 
DP1.  Hence, it was concluded that DP1 and TRIP-Br1 functionally interacted as part 
of a larger transcriptional regulatory complex.  The current thesis explores the 
possible regulatory mechanisms that may underlie the physiologic significance of the 
interaction between hTRIP-Br1, DP1 and other components of this regulatory 
complex.   
 
To examine the TRIP-Br1-DP1 interaction in greater detail, ectopically expressed 
(tagged) proteins and a series of deletion mutants derived from hTRIP-Br-HA and 
DP1 were generated.  hTRIP-Br1-HA and DP1 consistently co-immunoprecipitated, 
confirming the previously published of a direct protein-protein interaction between 
these proteins both in vitro and in vivo (14) [6].  Furthermore, co-
immunoprecipitation studies revealed the existence of a multiprotein complex which 
included hTRIP-Br1, DP1, E2F1 and p53 (Figures 14 and 20).  While it is possible 
that DP1 can form separate complexes with hTRIP-Br1, E2F1 and p53, respectively, 
the immunoprecipitation data presented collectively suggest the existence of a 
multiprotein complex that contains all of these proteins.  In order to determine if DP1, 
hTRIP-Br1, E2F1 and p53 form a quaternary complex through protein-protein 
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interactions among themselves, subsequent experiments were conducted to examine 
the relationship of these protein-protein interactions within the larger multiprotein 
transcriptional complex. 
 
In the course of the co-immunoprecipitation studies, it was also observed from the 
whole cell lysate (expression) controls that the protein levels of hTRIP-Br1-HA were 
affected by the co-overexpression of E2F1 and/or DP1.  This observation strongly 
suggested that hTRIP-Br1-HA was likely to be post-translationally regulated, leading 
us to pursue further investigations of this observation.  The potential significance of 
the findings is discussed later in this section. 
 
Studies utilizing the hTRIP-Br1-HA mutants revealed novel insights into structure-
function relationships.  The hTRIP-Br1 putative functional domains were mapped 
previously [6] and are shown in the upper panel of Figure 16.  The hTRIP-Br1 protein 
is envisaged to have an N-terminal half comprised of protein-protein interaction 
domains that may have function n a regulatory capacity, while the C-terminal half is 
primarily responsible for transcriptional co-activation.  The co-immunoprecipitation 
studies confirmed this structure-function relationship particularly as the C-terminal 
deletion mutants showed no significant difference in their ability to co-
immunoprecipitate DP1 (Figure 17, right panel).   Furthermore, these mutants 
displayed a decreased activity in a transcriptional assay on reconstituted E2F1/DP1 
on a heterologous reporter construct (Figure 35).  Taken together, the data infers that 
DP1 is likely to bind to the N-terminal half of hTRIP-Br1.  
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Notably, the N-terminal deletion mutants displayed a more varied phenotype.  The 
first 11 residues were postulated to contain the nuclear localization signal [6] and 
were therefore not deleted.  Deletion up to the 40th residue of hTRIP-Br1-HA did not 
affect its ability to co-immunoprecipitate DP1.  However, absence of the region 
containing residues 40 to 121 diminished hTRIP-Br1-HA interaction with DP1.  
Additional deletion mutants were used in an attempt to fine map the DP1 interaction 
domain on hTRIP-Br1.  It appeared that the smallest N-terminal mutant that exhibited 
binding impairment to DP1, and hence was unable to effectively co-
immunoprecipitate DP1, was the hTRIP-Br1-HA mutant lacking residues 12-50 (∆12-
50) (Figure 18).  An additional observation was that the expression of the protein was 
not comparable to that of the wild-type protein.  This may have affected the co-
immunoprecipitation and cause false negatives. It is also possible that the functional 
integrity of the heptad repeat is compromised or entirely abrogated in the mutants that 
do not co-immunoprecipitate DP1 as gross deletion mutants may be mis-folded.   
Nonetheless, since the ∆12-40 and 1-121 mutant could interact with DP1 (Figure 17, 
right panel lane 3 and left panel lane 5, respectively) but not ∆12-121 (Figure 18, lane 
2), the results suggest that the minimal region for binding to DP1 lay between 
residues 40 to 121 on hTRIP-Br1-HA (Figure 41).  This inference, however, should 
be further verified through the use of an hTRIP-Br1-HA ∆40-50 deletion mutant or 
heptad repeat single site-specific mutants.  Furthermore, the subject domain or 
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The co-immunoprecipitation findings were consistent with observations from the 
confocal microscopy of immuno-stained cells co-overexpressing both hTRIP-Br1-HA 
and T7-DP1.  It was demonstrated that hTRIP-Br1-HA was a nuclear protein and 
undetectable in the cytoplasm, according to our conditions.  T7-DP1 alone had an 
even distribution throughout the cell.  However, T7-DP1 was observed to co-localize 
with hTRIP-Br1-HA in the nucleus, indicating that the hTRIP-Br1-HA—T7-DP1 
interaction was essential for T7-DP1 to co-translocate into the nucleus (Figure 32).  
Considering the observations from the co-immunoprecipitation studies, hTRIP-Br1-
HA N-terminal deletion mutants were tested for T7-DP1 nuclear co-localization.  
Similar to the co-immunoprecipitation studies, it was observed that hTRIP-Br1-HA 
mutants that were unable to interact with DP1 also exhibited the inability to induce 
T7-DP1 nuclear co-localization (Figure 34 — ∆12-50, ∆12-73, ∆12-90, and ∆12-
121).  Furthermore, it was noted that these hTRIP-Br1-HA mutants did not present a 
clear nuclear localization.  These results demonstrate that the interaction between co-
overexpressed hTRIP-Br1-HA and T7-DP1 (mediated by the heptad repeat) influence 
the extent of localization of DP1 into the nucleus.  This property may affect the 
physiological fate of DP1 in the cell. 
 
Exogenously expressed DP1 had exhibited relatively strong binding with hTRIP-Br1-
HA and E2F1.  The DP1 ∆205-277 mutant was previously reported to be unable to 
bind to E2F1 [36].  The DP1 ∆205-277 mutant was therefore employed in an attempt 
to dissect the DP1/E2F1 and DP1/hTRIP-Br1 interactions (and/or functions).  The 
DP1 ∆205-277 mutant was well-expressed but unable to co-immunoprecipitate with 
hTRIP-Br1-HA (Figure 19).  This observation strongly suggested that the hTRIP-Br1 
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interaction domain may lie within, or at least partially within, DP1 residues 205-277.  
The ∆205-277 region also encompasses the DP-conserved box 1 and 2 (the entire 
DCB1 and the N-terminal 18 residues of DCB2) (Figure 38) [87, 95].  DP1 
interaction with E2F family proteins requires the DEF box (residues 146-204) [95], 
while the adjacent DCB1 and DCB2 domains of the DP1 dimerization domain may 
serve to interact with other proteins such as hTRIP-Br1 and/or p53.  It has been 
reported that p53 interacts with DP1 and that the binding/interaction region on DP1 
was maps to a relatively large region including residues 171-331 (Figure 38) [95].  It 
was recently discovered that DP1 had two additional isoforms, namely DP1α and 
DP1β (Figure 39) [40].    Both DP1α and DP1β isoforms lack certain C-terminal 
segments present in wild-type DP1 and are shorter (1-278 and 1-357, respectively) 
compared to the 410 residue wild-type DP1 (Figure 40).  Interestingly, DP1α was not 
able to interact with E2F1 although it had the dimerization domain from residues 192-
273 and an intact DEF box.  This observation was contrary to previous reports that 
DP1 ∆205-277 could not bind E2F1 [95].  Therefore, the simplest explanation for this 
apparent paradox would be that in addition to the DEF box, the DCB2 domain (259-
315) is required for E2F1 binding, since both the DP1 ∆205-277 mutant (missing 
residues 259-277 of DCB) and the DP1α isoform (missing residues 273-315 of 
DCB2) lacked slightly overlapping portions encompassing the entire DCB2 domain 
(Figure 38).  This notion is further validated by the fact that DP1β, containing a 
dimerization domain (192-316), interacts with E2F1 [40].  Based on the reported 
binding properties of these DP1 isoforms, together with the observation that DP1 
∆205-277 did not co-immunoprecipitate with hTRIP-Br1-HA, it is proposed that the 
hTRIP-Br1 binding lies principally within the DCB1 domain of DP1.  Considering 
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that the DCB1 domain lies within the p53 binding region, which spans part of the 
DEF box and includes the DCB1 and DCB2 domains, a novel hypothesis can be 
derived — that hTRIP-Br1 and p53 may compete for DP1 interaction.  The previous 
results support such a hypothesis since p53 was indeed observed to compete with 
hTRIP-Br1-HA for DP1 interaction in co-immunoprecipitation assays (Figure 22).   
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FIGURE 38 DP-1 domain structure.   
 
Adapted from Sorensen et. al. [95].  The main functional domains of DP1 are shown 
schematically.  The DNA binding region includes the DEF box (DP E2F box) 
domain.  p53 binding region consists partially of the DEF box, DCB1 and DCB2 
domains (DP-conserved box 1 and box 2, respectively).  The region 205-277 covers 
mainly DCB1 and the first 18 residues of DCB2, was deleted in the DP1 ∆205-277 
mutant.  DP1α isoform possessed the dimerization domain residues192-273 and 
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FIGURE 39 Alignment of DP1 wild-type with DP1α and DP1β.   
 
Figure adapted from Ishida et. al. [40], showing the differences between DP1α and 
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It was recently reported that hTRIP-Br1 (p34SEI-1) specifically stimulated the 
transactivation function of p53, although the authors suggested that the mechanism 
did not involve direct interaction between these proteins based on unpublished data 
[27]. The in vitro binding analysis demonstrated that there was no detectable direct 
interaction between p53 and hTRIP-Br1 (Figure 23).  However, it was apparent that 
p53 co-immunoprecipitated with hTRIP-Br1-HA as demonstrated by dose-dependent 
co-immunoprecipitation analyses (Figure 24).  It is likely that the relationship 
between the protein subunits of the E2F transcriptional complex is indeed intricate.  
Although no direct interaction between hTRIP-Br1 and p53 was observed in vitro, the 
co-immunoprecipitation studies demonstrated that both p53 and hTRIP-Br1 could be 
pulled down with an antibody against DP1, support by the existence of a 
E2F1/DP1/hTRIP-Br1-HA/p53 quaternary complex in vivo (Figure 20)  p53 is known 
to interact with the other components of this complex such as E2F1 and DP1.  In 
order to further elucidate the functional relationships between hTRIP-Br1 with E2F1, 
DP1 and p53 within this transcription complex, more detailed studies using various 
combinations of mutants of all subunits of the quaternary complex combined with 
protein structural determination using mass spectroscopy-based platforms is required, 
which are beyond the scope of this thesis. 
 
It was observed from the whole cell lysate immunoblots of immunoprecipitation 
experiments that co-overexpression of DP1 with hTRIP-Br1-HA resulted in higher 
protein levels of the latter (Figure 14, 15 and 20).  The studies of cycloheximide-
treated cells support a mechanism by which co-overexpression of DP1 leads to 
stabilization of hTRIP-Br1-HA protein, as evidenced by its accumulation and slower 
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rate of degradation (Figure 25).  The effect of DP1 on inhibiting hTRIP-Br1-HA 
degradation was shown to be specific since the ‘stabilization’ effect of DP1 co-
overexpression on hTRIP-Br1-HA was dose-dependent, Cyclin D degradation was 
unaffected and hTRIP-Br1 mRNA levels were unchanged and did not correlate with 
protein expression levels (Figures 27 and 28A).  Therefore, DP1 post-translationally 
regulates hTRIP-Br1 protein levels through a mechanism that specifically inhibits 
hTRIP-Br1 degradation.  A similar form of the interaction-post-translational 
regulation relationship has been previously observed for the case of E2F1 and p53, 
where E2F1 not only interacts with p53 but also stabilizes p53 from protein 
degradation [96].   The observed “co-operative stability” was recently been described 
as a mechanism where protein subunits degrade less rapidly when associated in 
multimeric complexes [97, 98]. 
 
DP1 could stabilize hTRIP-Br1 either by simple interaction with hTRIP-Br1, which 
masks the degradation signals or domains; or by co-localization in the nucleus as a 
result of the interaction between DP1 and hTRIP-Br1-HA.  The notion that DP1 
interaction conferred protein stability to hTRIP-Br1-HA via exclusion from the 
proteosomal degradation pathways was tested using MG132 treatment.  MG132 has 
been conventionally used as a tool for determination of protein turnover via the 26S 
proteosome [52, 88, 89, 99, 100].  MG132 treatment resulted in an accumulation of 
hTRIP-Br1-HA within 2 hours (Figure 29).  DP1 co-overexpression further 
augmented the protein accumulation.  The higher initial levels of hTRIP-Br1-HA 
associated with DP1 co-overexpression suggests that hTRIP-Br1-HA was likely to be 
inhibited from degradation through DP1 interaction even prior to MG132 treatment.  
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In addition, it was demonstrated that MG132 or lactacystin treatment induced an 
accumulation of hTRIP-Br1-HA protein (Figure 30) [93].  Not unexpectedly, the 
kinetics of hTRIP-Br1-HA accumulation was slower following lactacystin treatment8.  
Together with previous observations for cycloheximide treated cells co-
overexpressing DP1 and hTRIP-Br1, it can be concluded that hTRIP-Br1-HA 
degradation through the 26S proteosomal pathway is hindered by DP1 interaction. 
 
Having determined the respective hTRIP-Br1 and DP1 interaction domains for these 
protein partners, as well as the fact that DP1 protects hTRIP-Br1 from the 26S 
proteosomal degradation pathway, the demonstration that direct interaction between 
DP1 and hTRIP-Br1 was necessary for the observed stabilization of hTRIP-Br1-HA 
in the setting of DP1 co-overexpression was tested.  When DP1 was co-expressed 
with wild-type hTRIP-Br1-HA and/or an array of deletion mutants, it was observed 
that the C-terminal deletion mutants exhibited a relatively similar degradation profile 
to wild-type hTRIP-Br1-HA indicating that DP1 stabilized the hTRIP-Br1-HA C-
terminal deletion mutants, presumably through the established interaction and 
stabilization mechanism discussed earlier.  As with the immunoprecipitation data, N-
terminal mutants displayed significant differences in their degradation profiles 
following cycloheximide treatment (Figure 28).  The hTRIP-Br1-HA ∆12-40 mutant 
was rapidly degraded, to the extent that there was no detectable protein after 10 
minutes post-cycloheximide treatment.  Similarly, but to a lesser extent, the hTRIP-
Br1-HA ∆12-121 mutant had a shorter half-life following cycloheximide treatment as 
                                                 
8 The difference in protein accumulation response can be attributed to the specifities of both MG132 
and lactacystin.  Although both are used to inhibit the proteosome, the mechanisms of inhibition are 
distinctly difference and MG132 inhibition is reversible whereas lactacystin inhibition is irreversible. 
Lactacystin blocks multiple activities of the proteasome through modification of all of the major 
catalytically active β subunits whereas MG-132 is a peptide inhibitor.  
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compared to wild-type hTRIP-Br1-HA when co-overexpressed with DP1.  
Conversely, the hTRIP-Br1-HA ∆12-73 mutant appeared to be extremely stable with 
protein levels hardly diminishing (Figure 28), even without DP1 co-overexpression 
(Figure 17, upper panel, lane 4). 
 
A model which direct interaction with DP1 is necessary for the observed 
accumulation of hTRIP-Br1-HA is envisaged.  Consistent with this model, the ∆12-
121 mutant that does not co-immunoprecipitate DP1, had a turnover rate that was 
faster than wild-type hTRIP-Br1 in the presence of DP1.  The inability of a hTRIP-
Br1-HA deletion mutant to interact with DP1 would be expected to result in a faster 
turnover rate.  However, this was not always the case as observed with ∆12-40 and 
∆12-73.  The ∆12-40 mutant interacted with DP1 to a similar extent (Figure 17, 
lane3) but had an extremely rapid turnover.    Conversely, ∆12-73 did not interact 
with DP1 yet exhibited the most stable kinetics of protein degradation of all the 
hTRIP-Br1-HA proteins following cycloheximide treatment.  The apparent 
contradictory observations for mutants ∆12-40 and ∆12-73 may reflect additional 
changes in protein structure and function resulting from the removal of specific amino 
acid residues.  In the case of hTRIP-Br1-HA ∆12-40, it is also possible that the 
internal deletion disrupted protein secondary structure such that it exposed a putative 
degradation signal, likely to be within residues 40-73 (Figure 41).  Although DP1 
could bind to this mutant, the degradation signal may have had a dominant effect.  In 
the case of hTRIP-Br1-HA ∆12-73, the putative degradation signal would also have 
been internally deleted, thus conferring a high degree of stability to the mutant protein 
even in the absence of DP1 interaction.  The proposed model would be consistent 
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with the existence of just such a putative degradation signal within residues 40-73.  
The direct binding of DP1 to hTRIP-Br1 would stabilize the latter by masking and/or 
limiting access to the putative degradation signal within residues 40-73 (Figure D5), 
perhaps through simple steric hindrance.  A possible way to validate the existence of 
such a ‘degradation signal’ would be to fuse this region to a protein that is not broken 
down by cells, such as EGFP.  Observations on the degradation profile of 40-73—
EGFP fusion protein should provide further insights into the postulated physiologic 
regulatory function(s) of residues 40-73 in hTRIP-Br1. 
 
The relationship between the ability of hTRIP-Br1-HA to bind to co-overexpressed 
DP1 and its transcriptional co-activation function was tested by measuring the 
transcriptional readouts for relevant hTRIP-Br1-HA mutant proteins.  ∆12-40 
exhibited significantly lower transcriptional co-activation, when co-overexpressed 
with E2F1/DP1 on an E2F-responsive reporter construct, as compared to wild-type 
hTRIP-Br1-HA (Figure 35).  Furthermore, this mutant appeared to have a slight 
inhibitory effect on E2F1/DP1 transcriptional activity.  This observation relates well 
with previous data on the rapid turnover of the ∆12-40 mutant protein despite 
retaining its ability to bind DP1.  On the other hand, the ∆12-73 mutant exhibited at 
least 50% higher transcriptional activation compared to wild-type hTRIP-Br1-HA.  
This enhanced activity can be a consequence of the stabilized levels of the protein.  
Since the ∆12-73 mutant cannot interact with DP1, a mechanism involving 
dimerization with endogenous hTRIP-Br1 would need to be invoked to explain the 
observed enhancement of co-activation associated with its overexpression. Notably, 
within the region containing residues 40-73, there exists a single lysine at position 52.  
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In an earlier attempt to screen for post-translational modifications, this lysine 52 
(K52) was conservatively changed to an arginine residue via site-directed 
mutagenesis (K52R mutant) to mimic an acetylated lysine residue.  When tested for 
transcriptional activity, the K52R mutant also exhibited a significantly higher 
transcriptional co-activation than wild-type.  
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FIGURE 40 Proposed schematic of hTRIP-Br1 domain structures. 
 
The locations of newly identified functional domains are shown: a novel putative DP1 
interacting region and the novel degradation signal.  The DP1 interacting region 
covers residues 40-73.  The putative degradation signal region contains a yet 
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It was also observed that E2F1 co-overexpression had an effect on the post-
translational protein level of hTRIP-Br1-HA (Figures 27 and 28 panel B).  However, 
the instead of increased protein levels as observed with DP1 co-expression, hTRIP-
Br1 protein levels became rapidly undetectable (Figure 26), indicating either a faster 
turnover rate or lower expression.  This observed effect was specific since increasing 
doses of E2F1 resulted in a correspondingly lower hTRIP-Br1-HA but not Cdk2 
protein levels (Figure 27 panel B).  The observed effect of E2F1 co-overexpression 
on hTRIP-Br1-HA was unlikely due to faster turnover as the degradation rates did not 
change significantly with E2F1 co-overexpression.  Instead, it was observed that there 
were significant differences in the initial expression levels of hTRIP-Br1-HA at time 
0 post-cycloheximide treatment (Figure 27 panel B).  A faster turnover would also 
have resulted in a rapid accumulation of protein levels when MG132 was used to 
inhibit degradation.  On the contrary, the accumulation of protein levels was 
relatively slow, which may be attributed to the significantly lower initial expression 
levels of hTRIP-Br1-HA at time 0 post-cycloheximide treatment.  E2F1 was 
previously reported to impose a similar effect on p53 protein levels when ectopically 
expressed — a phenomenon known as transcriptional squelching9 [101].  Since E2F1 
co-overexpression also had a similar effect on DP1 protein levels, it may have a 
similar effect of transcriptional squelching on hTRIP-Br1-HA.   
 
p53 was also found to co-immunoprecipitate with hTRIP-Br1-HA as part of the 
quaternary complex along with E2F1 and DP1.  The visualization of this interaction 
was only possible with MG132 treatment (Figures 20, 22 and 23) as p53 caused a 
                                                 
9 Transcriptional squelching is a process by which general transcriptional factors become sequestered 
from the transcrioptional machinery due to association with excess transactivation domain.  
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rapid turnover of the hTRIP-Br1-HA protein.  It was found that DP1 co-
overexpression stabilized hTRIP-Br1-HA protein levels post-cycloheximide 
treatment.  However, co-overexpression with p53 and DP1 resulted in a more rapid 
turnover of hTRIP-Br1-HA (Figure 31).  This observation, together with the results of 
co-immunoprecipitation data, suggests that p53 overexpression can indirectly regulate 
hTRIP-Br1 by competitive binding to DP1, thus liberating free hTRIP-Br1 that 
subsequently marked for degradation.     
 
p53 has been shown to suppress DP1 expression by transcriptional squelching in a 
manner similar to E2F1; this suppression was alleviated with MG132 treatment [101].  
A similar mechanism may account for the observed effect that co-overexpression of 
p53 exerted on hTRIP-Br1-HA protein levels as observed in Figure 21.  It appears 
possible that p53 suppressed hTRIP-Br1-HA expression via transcriptional 
squelching (Figure 31).  Previously, it was reported that p53 down-modulated the 
CMV enhancer/promoter used in many vector constructs [102].  The conclusion from 
this report is a likely explanation for the observed p53 effect imposed upon hTRIP-
Br1-HA protein level expression.  Therefore, the observations from Figure 21 may be 
questionable without an internal control.   To differentiate between the p53 
modulation on CMV promoters and the protein-protein influence on hTRIP-Br1-HA 
protein levels, an internal control with the same vector construct but different gene 
could be utilized.   However, since the p53-modulation was reported to be alleviated 
by MG132, it is assumed that with MG132 treatment, the artifact of p53 modulation 
is negligible.  Therefore, the observation in Figure 32 remains valid that co-
overexpression of p53 does affect hTRIP-Br1-HA protein expression levels since 1) 
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MG132 was used; and 2) DP1 was co-overexpressed with pCMV/DP1 plasmid 
construct (as it doubles up as an internal control). 
 
It was proposed a model in which the direct interactions between hTRIP-Br1-HA and 
DP1 represents a form of post-translational regulation of the hTRIP-Br1 protein level 
within a cell based on the protein level of a key binding partner (e.g. DP1) that can 
mask a degradation signal and thereby prevent hTRIP-Br1 from being degraded 
through the 26S proteosomal pathway.  Another possible mechanism of post-
translational regulation that involves protein interaction is (co-)localization of 
proteins.  Eukaryotic cells have a nuclear membranes that divides the nucleoplasm 
from the cytoplasm.  Since, transcriptional regulatory activities occur in the nucleus, 
it is expected that transcriptional regulatory proteins would require a form nuclear 
import to reach the compartment which they carry out their function.  DP1 is notable 
for the absence of a nuclear localization signal, consistent with the localization of its 
free form in the cytoplasm [36].  As part of the E2F/DP transcriptional regulatory 
complex, it has been established that DP1 relies on its interaction with E2F1 to enter 
the nucleus and together initiate a myriad of transcriptional activities.  On the other 
hand, hTRIP-Br1 was demonstrated to be a nuclear protein (Figure 32 and 34) and 
could co-localize T7-DP1 into the nucleus.   
 
The ability of hTRIP-Br1-HA to affect T7-DP1 co-localization into the nucleus 
makes functional sense with all of the observations noted previously.  The 
relationship between hTRIP-Br1 and DP1 can be envisaged as such: that hTRIP-Br1 
binds with DP1, and as a consequence, hTRIP-Br1 is stabilized and protected from 
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degradation (possibly through steric hindrance of post-translational modifications to 
mark hTRIP-Br1 for degradation).  The same direct interaction allows hTRIP-Br1 to 
translocate DP1 into the nucleus.  Within the nucleus, the hTRIP-Br1-DP1 complex 
can then recruit available E2F1 and other co-regulators to form a larger multi-protein 
transcription complex that regulates E2F-reesponsive genes.   
 
This hypothesis is analogous to the reported finding that the E2F1/DP1 complex is 
differentially regulated by ARF (p14ARF) [36].  Ectopically expressed T7-DP1 was 
also shown to be cytoplasmic, while and co-expression of E2F1 led to the co-
localization of T7-DP1 into the nucleus.  Furthermore, co-transfection with ARF 
resulted in T7-DP1 nucleolar localization and subsequent degradation.  ARF was also 
shown to regulate E2F1 in a similar manner as DP1.  However, when E2F1 and DP1 
were co-expressed, ARF was unable to co-localize either into the nucleolus and/or 
effect protein degradation.  It appears that ARF regulates both E2F1 and DP1 protein 
levels to ensure that there is a physiological balance between these two proteins.   
Taken together, an integrated model for the regulation of the E2F1, DP1 and hTRIP-
Br1 transcriptional regulator proteins can be proposed. 
 
In this model (Figure 41), DP1 is cytoplasmic and can be translocated into the 
nucleus by its interactions with either E2F1 and/or hTRIP-Br1, both of which have 
the independent ability to localize into the nucleus.  Within the nucleus, free E2F1 is 
co-localized into the nucleolus and rapidly degraded through its interaction with ARF.  
If DP1 is available, there would be a preferential formation of the E2F1/DP1 
heterodimer complex, and consequent activation of transcription given appropriate 
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conditions.  Free hTRIP-Br1 within the nucleus is degraded rapidly, through the 26S 
proteosomal pathway.  It is also possible that hTRIP-Br1 can interact with the pre-
formed E2F1/DP1 complexes and the ternary E2F1/DP1/hTRIP-Br1 complex confers 
transcriptional activation through the previously proposed “integrator model” [6, 94].  
However, DP1 may also be able to translocate into the nucleus by its interaction with 
hTRIP-Br1.  In the event of hTRIP-Br1/DP1 complex formation and translocation 
into the nucleus, hTRIP-Br1 is stabilized and accumulates until E2F1 (or possibly 
ARF) is present.  Furthermore, when the E2F1/DP1/hTRIP-Br1 ternary complex is 
activated and performs its transcriptional activities, the complex is then rapidly 
degraded in a feedback loop-control mechanism.  This self-attenuation mechanism is 
in place to regulate the activity of the transcriptional complexes activity, and may 
involve ARF-associated proteolytic degradation. 
 
Table 3 summarizes the properties of hTRIP-Br1-HA that were characterized in this 
thesis.  From the data, it is evident that the C-terminal half of hTRIP-Br1-HA may 
play a minor role in protein regulation.  The main function appears to correlate with 
the putative domain structure, whereby the C-terminal half contains the 
transactivation domain and primarily regulates the transcriptional co-regulation 
properties of hTRIP-Br1-HA, as shown by the transcriptional assays.  Notably, the N-
terminal half of hTRIP-Br1-HA was demonstrated to contain putative domains 
involved in protein-protein interaction and the regulation of protein function through 
mechanisms such as direct effects on protein activity, stabilization and localization.  
The protein-protein interaction with DP1 was narrowed to a region spanning the 
heptad repeat of hTRIP-Br1-HA (also similar to the SERTA domain), as 
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demonstrated by the DP1 interaction with the N-terminal deletion mutants.  This 
interaction is envisaged to aid in protein stabilization since the loss of protein-protein 
interaction between hTRIP-Br1-HA and DP1 resulted in protein instability except for 
the hTRIP-Br1-HA ∆12-73 mutant, which was proposed to lack a degradation domain 
within residues 40-73.  The localization of hTRIP-Br1-HA and DP1 was also 
demonstrated to be interdependent on each binding partner.  Protein-protein 
interaction, as determined by co-immunoprecipitation assays, was a requirement for 
T7-DP1 nuclear co-localization when co-overexpressed with hTRIP-Br1-HA (Table 
3, ∆12-50 to ∆12-121 mutants).  On the other hand, protein activity, which was 
assayed by transcriptional co-activation together with E2F1/DP1, demonstrated that 
the C-terminal half of hTRIP-Br1-HA was essential.  Furthermore, deletion of the 
putative ‘degradation domain’ in ∆12-73 (and to a lesser extent in ∆12-50 and ∆12-
90) augmented hTRIP-Br1-HA transcriptional co-activation activity (Figure 35). 
 
The observations and data support a model in which hTRIP-Br1-HA is post-
translationally regulated.  This regulation is fundamentally influenced by the ability 
of hTRIP-Br1-HA to interact with DP1 through protein-protein mediated by the 
proposed interacting domains within each binding partner, namely the SERTA/heptad 
repeat domain in hTRIP-Br1-HA and the DCB1 domain in DP1.  The binding 
between DP1 and hTRIP-Br1-HA were observed to have at least two effects.  Firstly, 
DP1 binding to hTRIP-Br1-HA allowed the latter to be stabilized within the cells.  
This stabilization effect imposed on hTRIP-Br1-HA by DP1 interaction when co-
overexpressed was demonstrated to be specific.  Notably, hTRIP-Br1-HA 
stabilization (by DP1 co-overexpression) was concomitant with the presence of a 
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slightly higher molecular weight band of hTRIP-Br1-HA.  The increase in molecular 
weight suggests that there may have been a post-translational modification (PTM) 
where there was an addition of chemical groups to the protein. Since this band was 
also observed with MG132 treatment, it is likely that the PTM was ubiquitin, 
although it was not demonstrated in these experiments.  Preliminary experiments 
aimed at identifying post-translational modifications on hTRIP-Br1-HA using an 
array of antibodies specific for phospho-tyrosine and phospho-threonine, as well as 
antibodies that recognize N-acetyl, SUMO and ubiquitin groups, failed to identify the 
nature of the putative post-translational modification(s) of hTRIP-Br1-HA. 
 
There are several limitations to this study.  Firstly, the experiments were done without 
the availability of an antibody to endogenous hTRIP-Br1.  Therefore, a HA tagged 
version of hTRIP-Br1 was constructed for investigational purposes.  Detection of 
hTRIP-Br1 was based on the presence of the HA tag, which may conceivably have 
given rise to artifact by altering the properties of endogenous hTRIP-Br1.  This 
phenomenon, though possible, is presumed to be remote.  To further validate this 
presumption and confirm the observations presented earlier, similar experiments may 
be performed with a monoclonal antibody specific to hTRIP-Br1, which was only 
recently generated in our laboratory group.  Ours is the only group to date that has 
successfully produced a mouse monoclonal antibody against hTRIP-Br1 after 
multiple failed attempts owing to the high degree of homology between TRIP-Br1 of 
murine and human origin.  All other groups have similarly published data based on 
the overexpression of tagged TRIP-Br proteins. 
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Secondly, although deletion mutants in hTRIP-Br1 and DP1 have been isolated that 
failed to interact, further investigation may be carried out to comprehensively define 
the minimal binding region and, with single nucleotide mutations, determine critical 
residues involved in the interaction between hTRIP-Br1 and DP1.  Furthermore, the 
hTRIP-Br1 interaction domain on DP1 was identified based on a combination of 
deduction based on a careful review of published data to date and our own empirical 
observations.  Validation of the proposal that the DCB1 domain of DP1 is the hTRIP-
Br1 binding domain may be confirmed experimentally by co-immunoprecipitation 
studies using an isolated HA- or FLAG-tagged DCB1 domain. 
 
Next, E2F1 and DP1 function as heterodimers, and since hTRIP-Br1 was observed to 
have functional activities with DP1 almost exclusively, it leaves the question of the 
influence of E2F1 interaction with DP1 on the DP1-hTRIP-Br1 interaction and 
consequent activities.  Clearly, E2F1 has exhibited significant effects in the turnover 
of hTRIP-Br1-HA (Figures 27 and 28).  Delineating the effects of E2F1 would allow 
greater insights into the role and relationship between hTRIP-Br1 and DP1.  Perhaps 
this can be achieved through the use of a DP1 mutant that is able to bind with hTRIP-
Br1 but is unable to bind E2F1. 
 
Additionally, p53 was found to interact with TRIP-Br1 in the in vivo co-
immunoprecipitation studies.  However, direct binding was not observed with the 
IVT pull-down assay.  It was previously reported that there was no interaction 
between hTRIP-Br1 and p53.  Hence, the relationship between p53 and hTRIP-Br1 is 
currently inconclusive and warrants further investigations. 
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Lastly, it was noted that hTRIP-Br1-HA exhibited a protein band of higher molecular 
weight when co-overexpressed with DP1.  Attempts to identify this band with respect 
to potential PTMs using antibodies specific for phospho-tyrosine, phospho-threonine, 
N-acetyl, SUMO and Ubiquitin post-translational modification groups failed to 
identify the nature of the putative post-translational modification(s) of hTRIP-Br1-
HA.  Direct labeling with exogenous tagged-ubiquitin and ubiquitin labeling assays 
could be used as a better test for ubiquitination of hTRIP-Br1 in future experiments. 
Other alternative approaches would be to use mass spectrometry to identify any 
potential PTMs, followed by additional experiments (e.g. site-directed mutagenesis to 
block specific PTMs) to provide confirmatory functional data. 
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FIGURE 41 Proposed model for post-translational regulation of 
hTRIP-Br1 by DP1 integrated with proposed models 
of E2F1 and DP1 regulation by ARF.   
 
Legend: hTB1: hTRIP-Br1, ARF: p14ARF(alternate reading frame)
Cytoplasmic DP1 can bind to E2F1 (a) or hTRIP-Br1 (b).  When bound to E2F1, the 
E2F1/DP1 heterodimeric complex is formed and DP1 is translocated into the nucleus 
by its association with E2F1 (c).  The E2F1/DP1 complex can then bind DNA and/or 
hTRIP-Br1, to perform transcriptional activities as an activated transcriptional 
complex (g).  The activated complex self-attenuates after transcriptional activation 
and is broken down by the proteosomal pathway (h).  hTRIP-Br1 by itself has the 
intrinsic ability to translocate into the nucleus (d), and when it is in free form, it is 
rapidly broken down, presumably by the proteosomal pathway.  When DP1 is 
abundant, it binds hTRIP-Br1 (b) which then translocates DP1 into the nucleus (i) and 
the hTRIP-Br1/DP1 complex is stabilized due to DP1 binding.  This complex is able 
to bind E2F1 (j) and form the active ternary E2F1/DP1/hTRIP-Br1 complex.  E2F1 
(and DP1) by itself would be bound by ARF and then co-localized into the nucleolus 
where the protein is degraded rapidly.  This is a form of regulation to control and 
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TABLE 3 Summary of the properties hTRIP-Br1-HA proteins 
(wild-type and mutants). 
 







Nuclear         
localization of 
hTRIP-Br1-HA 




WT + + + +++ +++ 
hTRIP-Br1 
1-222 + + - +++ NA 
hTRIP-Br1 
1-186 + + -- +++ NA 
hTRIP-Br1 
1-121 + + -- +++ NA 
hTRIP-Br1 
∆12-121 - - + + - 
hTRIP-Br1 
∆12-90 - NA ++ + -  
hTRIP-Br1 
∆12-73 - +++ * +++ + +/- 
hTRIP-Br1 
∆12-50 +/- NA + + + 
hTRIP-Br1 
∆12-40 + - ** - ++ + 
 
* ∆12-73 mutant was stabilized independently and as a result of the deletion of 
residues 12-73. 
**  ∆12-40 mutant was highly unstable and was undetectable after 10 minutes 
with cycloheximide treatment. 
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